Disease by etiologic mechanism
MONDO:7770008A grouping class for human diseases classified by their etiologic mechanism, encompassing primarily intrinsic (genetic, genomic), primarily extrinsic (e.g., infections, toxins, radiation), and complex multifactorial (e.g. nutritional) causes.
59996 clinical trials for this condition and its sub-types, 0 tagged with Disease by etiologic mechanism itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Disease by etiologic mechanism
-
Cancer or benign tumor 0 trials · 33,018 incl. sub-types
5 sub-types
- Neoplastic disease or syndrome 7 trials · 32,686 incl. sub-types Sub-types →
- Precancerous condition 51 trials · 518 incl. sub-types Sub-types →
- Hyperplasia 5 trials · 272 incl. sub-types Sub-types →
- Polyp 14 trials · 200 incl. sub-types Sub-types →
- Cancer-related condition 16 trials · 36 incl. sub-types Sub-types →
-
Disease of genetic or genomic mechanism 2 trials · 18,330 incl. sub-types
2 sub-types
- Hereditary disease 193 trials · 18,187 incl. sub-types Sub-types →
- Chromosomal disorder 13 trials · 276 incl. sub-types Sub-types →
-
Disease of primarily extrinsic mechanism 0 trials · 10,578 incl. sub-types
7 sub-types
- Infectious disease 295 trials · 8,205 incl. sub-types Sub-types →
- Post-infectious disorder 2 trials · 1,770 incl. sub-types Sub-types →
- Disease related to transplantation 30 trials · 538 incl. sub-types Sub-types →
- Poisoning 69 trials · 311 incl. sub-types Sub-types →
- Occupational disorder 59 trials · 171 incl. sub-types Sub-types →
- Iatrogenic disease 19 trials · 136 incl. sub-types Sub-types →
- Radiation-induced disorder 7 trials · 93 incl. sub-types Sub-types →
-
Nutritional disorder 132 trials · 4,162 incl. sub-types
7 sub-types
- Overnutrition 15 trials · 3,247 incl. sub-types Sub-types →
- Nutritional deficiency disease 235 trials · 508 incl. sub-types Sub-types →
- Eating disorder 157 trials · 362 incl. sub-types Sub-types →
- Lactose intolerance 9 trials · 10 incl. sub-types Sub-types →
- Potassium deficiency disease 4 trials · 5 incl. sub-types Sub-types →
- Refeeding syndrome 4 trials
- Hemorrhagic disease of newborn 1 trial
-
Idiopathic disease 1 trial · 1,282 incl. sub-types
79 sub-types
- Fibromyalgia 279 trials
- Idiopathic interstitial pneumonia 10 trials · 219 incl. sub-types Sub-types →
- Idiopathic scoliosis 66 trials · 181 incl. sub-types Sub-types →
- Acquired idiopathic inflammatory myopathy 67 trials · 159 incl. sub-types Sub-types →
- Juvenile idiopathic arthritis 107 trials · 115 incl. sub-types Sub-types →
- Idiopathic urticaria 0 trials · 66 incl. sub-types Sub-types →
- Idiopathic membranous glomerulonephritis 50 trials
- Idiopathic hypersomnia 28 trials Sub-types →
- Idiopathic nephrotic syndrome 13 trials · 24 incl. sub-types Sub-types →
- Sudden unexpected death in pediatrics 1 trial · 17 incl. sub-types Sub-types →
- Cellular phase chronic idiopathic myelofibrosis 16 trials
- Idiopathic pulmonary arterial hypertension 15 trials
- Idiopathic spontaneous coronary artery dissection 15 trials
- Idiopathic bilateral vestibulopathy 14 trials
- Idiopathic achalasia 12 trials
- Pediatric acute-onset neuropsychiatric syndrome 8 trials · 10 incl. sub-types Sub-types →
- Idiopathic aplastic anemia 9 trials
- Persistent idiopathic facial pain 9 trials
- Idiopathic gastroparesis 8 trials
- Idiopathic recurrent pericarditis 8 trials
- Idiopathic CD4 lymphocytopenia 7 trials
- Idiopathic camptocormia 7 trials
- Myelodysplastic syndrome with ring sideroblasts 7 trials
- Idiopathic CD4-positive T-lymphocytopenia 6 trials
- Idiopathic torsion dystonia 6 trials Sub-types →
- Chronic idiopathic neuropathy 5 trials
- Idiopathic malabsorption due to bile acid synthesis defects 4 trials
- Idiopathic bronchiectasis 3 trials Sub-types →
- Idiopathic cardiomyopathy 2 trials · 3 incl. sub-types Sub-types →
- Idiopathic hypercalciuria 3 trials
- Idiopathic anaphylaxis 1 trial
- Idiopathic avascular necrosis 1 trial
- Idiopathic central precocious puberty 1 trial
- Idiopathic mast cell activation syndrome 1 trial
- Idiopathic posterior uveitis 1 trial
- Macular telangiectasia type 1 1 trial
- Nonimmune chronic idiopathic neutropenia of adults 1 trial
- Basal ganglia calcification, idiopathic, 1 0 trials
- Basal ganglia calcification, idiopathic, 4 0 trials
- Basal ganglia calcification, idiopathic, 5 0 trials
- Basal ganglia calcification, idiopathic, 6 0 trials
- Basal ganglia calcification, idiopathic, 7, autosomal recessive 0 trials
- Basal ganglia calcification, idiopathic, 8, autosomal recessive 0 trials
- Basal ganglia calcification, idiopathic, childhood-onset 0 trials
- Benign idiopathic neonatal seizures 0 trials
- Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia 0 trials
- Diffuse idiopathic skeletal hyperostosis 0 trials
- Edema, familial idiopathic, prepubertal 0 trials
- Familial idiopathic dilatation of the right atrium 0 trials
- Idiopathic acute transverse myelitis 0 trials
- Idiopathic anterior uveitis 0 trials
- Idiopathic congenital hypothyroidism 0 trials
- Idiopathic copper-associated cirrhosis 0 trials
- Idiopathic corneal edema 0 trials
- Idiopathic disseminated cytomegalovirus infection 0 trials
- Idiopathic dropped head syndrome 0 trials
- Idiopathic ductopenia 0 trials
- Idiopathic eosinophilic pneumonia 0 trials Sub-types →
- Idiopathic granulomatous myositis 0 trials
- Idiopathic hemiconvulsion-hemiplegia syndrome 0 trials
- Idiopathic juvenile osteoporosis 0 trials
- Idiopathic linear interstitial keratitis 0 trials
- Idiopathic localized lipodystrophy 0 trials
- Idiopathic neonatal atrial flutter 0 trials
- Idiopathic panuveitis 0 trials Sub-types →
- Idiopathic peliosis hepatis 0 trials
- Idiopathic peripheral autonomic neuropathy 0 trials
- Idiopathic phalangeal acro-osteolysis 0 trials
- Idiopathic progressive polyneuropathy 0 trials
- Idiopathic pulmonary artery dilatation 0 trials
- Idiopathic recurrent stupor 0 trials
- Idiopathic severe pneumococcemia 0 trials
- Idiopathic syringomyelia 0 trials
- Intestinal pseudoobstruction, neuronal, chronic idiopathic, X-linked 0 trials
- Macular telangiectasia type 3 0 trials
- Polyhydramnios, chronic idiopathic 0 trials
- Priapism, familial idiopathic 0 trials
- Recurrent idiopathic neuroretinitis 0 trials
- Tremor, hereditary essential, and idiopathic normal pressure hydrocephalus 0 trials
Most studied deeper sub-types
Showing the 400 most recently updated of 22615 trials in this tab.
-
Radical new schedule aims to cure High-Risk ewing sarcoma
Cure Recruiting nowThis study tests a new treatment schedule for people with metastatic Ewing sarcoma, a rare and aggressive cancer. The approach uses an intense first attack on cancer cells, followed by targeted strikes and long-term maintenance to wipe out remaining cells. The goal is a cure. The…
Phase 1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Cure
Last updated Sep 20, 2026 00:00 UTC
-
Gene therapy aims to cure inherited immune disorder
Cure Recruiting nowChronic granulomatous disease (CGD) caused by p47phox deficiency is a rare, life-threatening genetic disorder that leaves people vulnerable to severe infections. Standard treatments include daily antibiotics and antifungal drugs, but they do not fix the underlying genetic defect.…
Phase 1/2 • Sponsor: Somagenetix AG • Aim: Cure
Last updated Sep 19, 2026 00:00 UTC
-
Engineered t cells target FLT3 in Hard-to-Treat leukemia
Cure Recruiting nowResearchers are testing a new cell therapy called anti-FLT3 CAR-T (HG-CT-1) in adults and children with acute myeloid leukemia (AML) that has come back or stopped responding to standard treatment. The study is a Phase 1 dose-escalation trial, meaning its first goal is to find out…
Phase 1 • Sponsor: Hemogenyx Pharmaceuticals LLC • Aim: Cure
Last updated Sep 19, 2026 00:00 UTC
-
New universal flu vaccine enters human testing
Vaccine Recruiting nowThis study tests an experimental flu vaccine called BPL-1357, given as a shot or nasal spray, to see if it is safe and can protect against multiple flu types. About 129 healthy adults aged 18-55 will receive the vaccine or a placebo, then be exposed to a flu virus in a controlled…
Phase 2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Vaccine
Last updated Sep 20, 2026 00:00 UTC
-
Can mRNA technology outsmart the flu in older adults?
Vaccine Recruiting nowThis large phase 3 trial compares an investigational mRNA flu vaccine with a licensed flu vaccine in adults aged 65 and older. Each participant receives a single injection and is followed through the flu season. Researchers measure how well the mRNA vaccine prevents laboratory-co…
Phase 3 • Sponsor: GlaxoSmithKline • Aim: Vaccine
Last updated Sep 20, 2026 00:00 UTC
-
New nasal spray COVID booster enters human testing
Vaccine Recruiting nowThis early-stage trial is testing a new COVID-19 booster vaccine called OCU500, which is given as a nasal spray or inhaled mist instead of a shot. The study involves 80 healthy adults aged 18-64 who have already been vaccinated against COVID-19. Researchers are checking if the va…
Phase 1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Vaccine
Last updated Sep 20, 2026 00:00 UTC
-
New HIV vaccine booster trial launches: could it strengthen immunity?
Vaccine Recruiting nowThis early-stage trial is testing a new HIV vaccine booster called VRIPRO, given with an immune-boosting adjuvant, in 40 healthy adults aged 18-60 who previously received an HIV vaccine in the HVTN 706 study. Participants will get three shots over 24 weeks. The main goals are to …
Phase 1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Vaccine
Last updated Sep 20, 2026 00:00 UTC
-
Could a vaccine stop the virus behind mono, cancer, and MS?
Vaccine Recruiting nowThis early-stage study is testing two new vaccines (V350A and V350B) designed to prevent diseases caused by the Epstein-Barr virus (EBV), which can cause infectious mononucleosis and is linked to certain cancers and multiple sclerosis. The study will enroll 250 healthy adults and…
Phase 1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Vaccine
Last updated Sep 19, 2026 00:00 UTC
-
New hope for uncontrolled muscle movements: valbenazine trial targets stubborn TD symptoms
Disease control Recruiting nowThis study tests whether valbenazine can reduce involuntary muscle movements (tardive dyskinesia) in adults who still have symptoms while taking or after stopping another similar drug. About 50 people with schizophrenia, bipolar disorder, or major depression will take valbenazine…
Phase 4 • Sponsor: Neurocrine Biosciences • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Hope for stargardt patients: new drug aims to slow blindness
Disease control Recruiting nowThis Phase 3 trial tests an oral drug called gildeuretinol acetate (ALK 001) in 230 people aged 8 to 45 with Stargardt disease, a genetic condition that causes progressive vision loss. Participants take the drug or a placebo daily for 24 months. The goal is to see if the drug can…
Phase 3 • Sponsor: Alkeus Pharmaceuticals, Inc. • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New hope for advanced cancer: experimental drug HMPL-A580 enters human trials
Disease control Recruiting nowThis early-phase trial tests an experimental drug called HMPL-A580 in 186 adults with advanced or metastatic solid tumors that cannot be removed by surgery. The study aims to find a safe dose and check for early signs that the drug shrinks tumors. It is currently recruiting parti…
Phase 1/2 • Sponsor: Hutchmed • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New drug trial aims to shrink painful lymphatic growths in kids and adults
Disease control Recruiting nowThis study tests alpelisib, a drug that targets a specific gene mutation (PIK3CA), in people with lymphatic malformations—abnormal growths of lymph vessels. The trial includes children and adults and compares alpelisib to a placebo to see if it can shrink the growths and ease sym…
Phase 2/3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Targeted radiation plus hormone therapy may slow Low-Volume prostate cancer spread
Disease control Recruiting nowThis phase II trial tests whether adding a targeted radiation drug (177Lu-PSMA-617) to standard hormone therapy, with or without additional hormone-blocking pills, can better control low-volume metastatic hormone-sensitive prostate cancer. The study enrolls men whose cancer has s…
Phase 2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New drug combo aims to tame tough lung cancer
Disease control Recruiting nowThis study tests a new drug combination (alisertib plus paclitaxel) in people with small cell lung cancer who have already tried other treatments. The main goal is to find safe doses and see what side effects occur. About 50 adults will take alisertib pills and receive paclitaxel…
Phase 2 • Sponsor: Puma Biotechnology, Inc. • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New immunotherapy combo aims to wipe out hidden colorectal cancer cells
Disease control Recruiting nowThis phase 2 trial tests whether two immunotherapy drugs, botensilimab and balstilimab, can clear tiny amounts of cancer DNA from the blood of people with stage II or III colorectal cancer who have completed standard treatment. The study enrolls 20 adults whose blood still shows …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Could an immunotherapy drug keep early lung cancer from returning?
Disease control Recruiting nowThis phase III trial is testing whether the immunotherapy drug atezolizumab, given after surgery, can prevent stage I non-small cell lung cancer from returning. About 336 patients who have had their tumor completely removed will be randomly assigned to receive either atezolizumab…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Lifeline for cancer patients: rollover study extends access to targeted drug opnurasib
Disease control Recruiting nowThis rollover study allows up to 40 people with KRAS G12C-mutated lung or other solid tumors who are already benefiting from opnurasib in a Novartis trial to keep receiving the drug. Participants continue their current dose of opnurasib alone or with TNO155 or trametinib. The goa…
Phase 1/2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Could Two-Drug cocktails tame stubborn inflammatory bowel disease?
Disease control Recruiting nowThis study tests whether combining risankizumab with either trosunilimab or ABBV-701 can safely reduce inflammation and improve symptoms in adults with moderately to severely active Crohn's disease or ulcerative colitis. Participants are randomly assigned to one of the combinatio…
Phase 2 • Sponsor: AbbVie • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Two-Drug combo targets leukemia that outsmarted its first treatment
Disease control Recruiting nowResearchers are testing whether adding an experimental drug called RVU120 to venetoclax can help adults with acute myeloid leukemia (AML) that has come back or stopped responding to earlier venetoclax-based treatment. The trial enrolls about 98 adults who have already failed a hy…
Phase 2 • Sponsor: Ryvu Therapeutics SA • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New pill combo aims to tackle tough leukemia
Disease control Recruiting nowThis early-stage trial tests two oral drugs, ziftomenib and quizartinib, together in adults with relapsed or hard-to-treat acute myeloid leukemia (AML) that has certain genetic markers. The goal is to find a safe and effective all-pill treatment for common AML subtypes. About 44 …
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Electric pulses aim to zap breast cancer tumors in early safety trial
Disease control Recruiting nowThis pilot study tests a device that uses short, high-frequency electrical pulses to shrink or destroy soft tissue tumors in people with metastatic breast cancer. The trial will enroll 20 adults with tumors near the skin that are at least 1 cm but no larger than 5 cm. The main go…
Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New combo aims to wipe out stubborn leukemia traces
Disease control Recruiting nowThis study tests whether two drugs, venetoclax and revumenib, can control minimal residual disease (MRD) in people with acute myeloid leukemia (AML). MRD means small numbers of cancer cells remain after initial treatment, raising the risk of relapse. The trial enrolls about 8 par…
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Experimental biologic AWT020 put to the test in Hard-to-Treat cancers
Disease control Recruiting nowResearchers are testing an experimental biologic called AWT020 in adults with advanced solid tumors that have worsened after at least one standard treatment. The phase 1 trial gives AWT020 every three weeks at increasing dose levels to find the highest dose people can tolerate an…
Phase 1 • Sponsor: Anwita Biosciences • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Watch and wait: could immunotherapy let some GI cancer patients avoid surgery?
Disease control Recruiting nowThis study looks at people with early-stage gastrointestinal cancers that have a mismatch repair deficiency, a feature that can make tumors respond well to immunotherapy. Part A is a registry that tracks all such patients, whether they have surgery or immunotherapy. Part B follow…
Sponsor: University Hospital, Basel, Switzerland • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New drug cocktail aims to shrink head and neck tumors before surgery
Disease control Recruiting nowThis study tests whether a combination of drugs (pembrolizumab and N-803, with or without special immune cells called PD-L1 t-haNK cells) can help shrink head and neck cancers before surgery. About 40 adults with untreated, HPV-negative head and neck cancer will receive these tre…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New shot aims to tame ulcerative colitis Flare-Ups
Disease control Recruiting nowThis study tests whether MK-8690, a drug given as a shot, can help people with moderate-to-severe ulcerative colitis achieve remission. About 100 adults who haven't responded well to other treatments will receive either MK-8690 or a placebo. The main goal is to see if more people…
Phase 2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Immunotherapy boost before surgery shows promise for rare urinary tract cancer
Disease control Recruiting nowThis study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy before surgery helps shrink tumors in people with high-grade upper urinary tract cancer. About 131 adults will be randomly assigned to receive either chemo alone or chemo plus durvalumab be…
Phase 2/3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New pill NP-101 tested in patients with Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial is testing an oral drug called NP-101 in 35 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and side effects, with a secondary look at whether the drug can shrink tumors. Because it is a Pha…
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New drug combo aims to control Hard-to-Treat prostate cancer
Disease control Recruiting nowThis study tests a new combination of two drugs (tulmimetostat and JSB462) in men with advanced prostate cancer that has spread and stopped responding to standard hormone therapy. The trial has two parts: first, finding the safest dose, then comparing the combination to usual car…
Phase 1/2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New combo therapy aims to boost remission in rare blood cancer
Disease control Recruiting nowThis study tests whether adding enasidenib to standard treatment (ASTX727) improves outcomes for people with a high-risk form of myelodysplastic syndrome (MDS) that has a specific gene mutation (IDH2). About 54 adults who have not had prior cancer therapy will be randomly assigne…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Promising drug cocktail targets tough blood cancers in kids
Disease control Recruiting nowThis study tests whether a combination of three drugs—calaspargase pegol-mknl, decitabine, and venetoclax—can help control relapsed or treatment-resistant T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LLy) in patients aged 1 month to 21 years. T…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New drug aimed at stopping lung rejection in transplant patients
Disease control Recruiting nowThis early-stage trial tests a drug called fostamatinib in 30 adults who have developed donor-specific antibodies after a lung transplant. These antibodies can attack the new lung and raise the risk of death. Participants take fostamatinib or a placebo for 8 weeks, along with the…
Phase 1 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Experimental pill SHY-ONC6 takes on Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests an experimental oral drug called SHY-ONC6 in people with advanced or metastatic solid tumors (including breast, colon, lung, pancreatic, and others) that have stopped responding to standard treatments. The study aims to find a safe dose and check for …
Phase 1 • Sponsor: SHY Therapeutics • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Could a weekly shot fix hormone chaos in teens with PCOS?
Disease control Recruiting nowThis study tests whether a weekly injection of semaglutide (a GLP-1 drug used for obesity) can improve the brain's reproductive hormone signals in obese adolescent girls with polycystic ovary syndrome (PCOS). Twenty girls aged 12–18 will receive the drug plus lifestyle advice for…
Sponsor: Nemours Children's Clinic • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Poop pills? stool transplants may ease immunotherapy side effects
Disease control Recruiting nowThis early-stage trial tests whether a stool transplant (FMT) can help cancer patients who develop severe diarrhea or colon inflammation from immune-checkpoint inhibitor drugs. About 40 patients with various cancers will receive the transplant via colonoscopy. The main goal is to…
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New drug targets Hard-to-Treat lung cancer in early trial
Disease control Recruiting nowThis phase 2 trial tests a drug called navlimetostat in about 130 people with advanced or metastatic non-small cell lung cancer that has a specific genetic change (MTAP deletion) and has worsened after other treatments. The main goal is to see if the drug can shrink tumors. Resea…
Phase 2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New drug could stop knee infections after replacement
Disease control Recruiting nowThis study tests whether an investigational drug called PLG0206 can prevent infections from coming back after knee replacement surgery. About 240 adults who need a special cleaning surgery (DAIR) for an infected knee joint will receive either PLG0206 or a placebo during the proce…
Phase 2/3 • Sponsor: Peptilogics • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New electric pulse therapy could replace radiation boost for prostate cancer
Disease control Recruiting nowThis study compares a new boost approach called irreversible electroporation (IRE) using the NanoKnife system against the standard radiation boost for men with intermediate-risk prostate cancer. All participants will receive standard stereotactic body radiation therapy (SBRT), bu…
Phase 3 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New drug rilvegostomig takes on keytruda in lung cancer showdown
Disease control Recruiting nowThis phase 3 study compares two immunotherapy drugs—rilvegostomig and pembrolizumab (Keytruda)—each combined with standard chemotherapy, as a first treatment for people with advanced squamous non-small cell lung cancer that has a specific protein (PD-L1). About 880 participants w…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New hope for tough prostate cancer: Immune-Engaging drug enters human trials
Disease control Recruiting nowThis early-phase trial tests a new drug, GSK5458514, designed to help the immune system attack prostate cancer cells. It is for men with metastatic castration-resistant prostate cancer that has spread and stopped responding to hormone therapy. The study will first find a safe dos…
Phase 1/2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Smart bomb for kidney cancer: imaging and radiation combo targets tough tumors
Disease control Recruiting nowThis trial tests a two-part approach for advanced clear cell kidney cancer that has stopped responding to standard treatments. First, an imaging injection (PD-32766D) lights up cancer cells that have a specific marker (CA9). If the scan shows the marker is present, participants t…
Phase 1 • Sponsor: PeptiDream Inc. • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Tiny implant aims to restore sight in eyes that resist standard AMD therapy
Disease control Recruiting nowResearchers are testing a new treatment called PAL-222 for people with neovascular age-related macular degeneration (AMD) whose disease has not responded to existing therapies. The study will enroll up to 10 adults aged 18 to 85 with this condition. Each participant will have a s…
Sponsor: PharmaBio Corporation • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New cell therapy trial aims to tame stubborn autoimmune diseases
Disease control Recruiting nowThis early-phase trial is testing an injection called GT719 in 10 adults with moderate to severe autoimmune diseases that haven't responded to other treatments. The main goal is to check safety and find the right dose. Researchers will also look for signs that the therapy might h…
Early phase 1 • Sponsor: Grit Biotechnology • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Radiation boosts cancer drug in Tough-to-Treat myeloma
Disease control Recruiting nowThis study tests whether adding low-dose radiation to the drug elranatamab can better kill cancer cells in people with multiple myeloma that has come back or not responded to treatment and has spread outside the bone. About 34 adults will receive the combination. The goal is to s…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Blood test may tell who needs extra immunotherapy after bladder cancer surgery
Disease control Recruiting nowThis large trial is testing whether a blood test that looks for tumor DNA can help decide who needs immunotherapy after surgery for muscle-invasive urothelial cancer. About 992 participants will be assigned to different treatment plans based on their blood test results. The goal …
Phase 2/3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Injectable hydrogel could ease back pain without surgery
Disease control Recruiting nowThis study tests a hydrogel implant injected into damaged spinal discs to treat degenerative disc disease. About 225 adults with chronic low back pain will receive either the implant or standard care like physical therapy. The goal is to see if the implant safely improves pain an…
Sponsor: ReGelTec, Inc. • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New drug combo shows promise in AML fight
Disease control Recruiting nowThis study tests whether adding the drug venetoclax to standard chemotherapy can better treat acute myeloid leukemia (AML) that is newly diagnosed or has come back. About 116 adults with AML or high-risk MDS will receive the combination. The goal is to see if the combo improves r…
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New hope for rare kidney cancer: drug trial targets tough tumors
Disease control Recruiting nowThis study tests a drug called sacituzumab tirumotecan in 20 people with a rare and aggressive kidney cancer (SMARCB1-deficient renal medullary carcinoma) that has worsened after at least one prior treatment. The goal is to see if the drug can shrink or control the cancer. Resear…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New drug targets tough pancreatic cancer in early trial
Disease control Recruiting nowThis phase 2 study tests an experimental drug called BT5528 in adults with metastatic pancreatic cancer that has spread and worsened after one prior treatment. The drug targets a specific protein on cancer cells. Researchers will measure how well it shrinks tumors and track side …
Phase 2 • Sponsor: BicycleTx Limited • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Targeted therapy boost for aggressive uterine cancer under study
Disease control Recruiting nowThis phase 3 trial tests whether adding targeted drugs (trastuzumab and pertuzumab) to standard chemotherapy can better shrink tumors in people with HER2-positive endometrial cancer. The study plans to enroll 360 participants with various stages of the disease. However, the trial…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New mRNA vaccine combo aims to prevent lung cancer recurrence in High-Risk patients
Disease control Recruiting nowThis phase 3 trial tests whether a personalized mRNA cancer vaccine (intismeran) alone or combined with an immunotherapy drug (pembrolizumab) can prevent non-small cell lung cancer from coming back after complete surgical removal. About 876 people with high-risk stage I lung canc…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New drug TAK-360 tested for Long-Term safety in sleep disorders
Disease control Recruiting nowThis study looks at the long-term safety and tolerability of the drug TAK-360 in people with narcolepsy (type 1 or 2) or idiopathic hypersomnia — conditions that cause severe daytime sleepiness. Participants who completed a previous TAK-360 study can join and will continue taking…
Phase 2/3 • Sponsor: Takeda • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Could a pill replace chemo for some breast cancers? major trial launches
Disease control Recruiting nowThis study compares two treatments for people with high-stage, estrogen-positive, HER2-negative breast cancer that has a low genetic risk of returning. One group gets standard hormone therapy plus a targeted pill (ribociclib), while the other gets chemotherapy first, then the sam…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New antiviral pill aims to keep High-Risk COVID patients out of hospital
Disease control Recruiting nowThis study tests whether the antiviral drug molnupiravir can prevent severe illness from COVID-19 in adults at high risk. About 3,000 non-hospitalized participants will take either molnupiravir or a placebo for 5 days. The main goal is to see if the drug reduces hospitalizations,…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New hope for rare leukemia: Four-Drug cocktail targets cancer cells
Disease control Recruiting nowThis phase 2 trial tests a new drug combination for adults newly diagnosed with primary plasma cell leukemia, a rare and aggressive blood cancer. The treatment includes CM336 (a bispecific antibody) plus three other drugs. The study aims to see how many patients achieve deep remi…
Phase 2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Could a probiotic help fight cancer? early trial launches
Disease control Recruiting nowThis early-stage trial is testing whether an oral probiotic called R-5780 is safe and tolerable when taken alongside a standard PD-1 checkpoint inhibitor in people with advanced solid tumors (like melanoma or certain skin cancers). About 33 adults whose cancer has not responded t…
Phase 1 • Sponsor: Rise Therapeutics LLC • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New combo aims for deeper remission in older leukemia patients
Disease control Recruiting nowThis phase II trial tests whether adding gilteritinib to the usual two-drug therapy (azacitidine and venetoclax) can help older or frail adults with a specific type of acute myeloid leukemia (FLT3-mutated) achieve deeper remission. About 147 participants will be randomly assigned…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Could a higher dose of this pill regrow hair in severe alopecia?
Disease control Recruiting nowThis study tests two daily doses (50 mg and 100 mg) of the medicine ritlecitinib in about 550 people aged 12 and older with severe alopecia areata, a condition causing significant hair loss on the scalp and body. The 50 mg dose is already approved, and researchers want to see if …
Phase 3 • Sponsor: Pfizer • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Can a new drug ASP388B take on advanced solid tumors?
Disease control Recruiting nowThis trial tests an experimental drug called ASP388B, given alone or alongside standard cancer therapies, in people with advanced solid tumors that have spread or cannot be removed by surgery. The study has two parts: the first finds a safe dose, and the second tests that dose in…
Phase 1/2 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New trial aims to improve radiation for large brain tumors
Disease control Recruiting nowThis phase 2 trial compares two standard radiation approaches for people with large brain metastases (tumors that spread from other cancers). One method gives two radiation doses a month apart; the other gives three daily doses. The study will track tumor control, side effects, a…
Phase 2 • Sponsor: Medical University of South Carolina • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New antibody combo shows promise in early cancer trial
Disease control Recruiting nowThis early-phase trial is testing an experimental drug called BI-1808, alone or with the immunotherapy pembrolizumab (Keytruda), in people with advanced cancers like ovarian cancer, T-cell lymphoma, and melanoma. The main goals are to check safety, find the best dose, and see how…
Phase 1/2 • Sponsor: BioInvent International AB • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Could a common arthritis drug tame rare immune disease symptoms?
Disease control Recruiting nowThis early study tests baricitinib, a drug already approved for other immune conditions, in 20 people with Job syndrome who also have lupus-like disease or eczema. Participants take the pill daily for 6 months. The main goal is to see if it is safe and tolerable, while also check…
Phase 1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Gene test could tailor chemo doses for rare cancer
Disease control Recruiting nowThis phase 2 trial is testing whether adjusting the dose of the drug belinostat based on a person's genetics can make treatment safer and more effective for high-grade neuroendocrine carcinoma. About 60 adults will receive belinostat along with two other chemotherapy drugs, cispl…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Can a daily nail film clear stubborn toenail fungus?
Disease control Recruiting nowResearchers are testing a topical filmogel device called URGO MICKAEL on mild to moderate toenail fungus. About 54 adults with one or two damaged big toenails apply the device daily for up to six months. The study measures whether fungal cultures from the treated nail turn negati…
Sponsor: CEN Biotech • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Triple-Drug cocktail targets kidney cancer brain metastases
Disease control Recruiting nowThis phase 2 trial is testing whether a combination of three drugs—nivolumab, ipilimumab, and cabozantinib—can help people with kidney cancer that has spread to the brain. The study will enroll 20 participants who have not had prior treatment for their brain metastases. The main …
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New Immune-Targeting drug surovatamig enters first human tests for arthritis and lupus
Disease control Recruiting nowThis Phase 1 trial tests surovatamig, a bispecific T-cell engager, in 48 adults with rheumatoid arthritis or systemic lupus erythematosus. The study gives the drug as injections in increasing doses to check safety, side effects, and how the body processes it. It is too early to k…
Phase 1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New injection aims to tackle Alzheimer's at its roots
Disease control Recruiting nowThis study tests a new drug called ARO-MAPT-SC in healthy people and those with early Alzheimer's. The goal is to check if it is safe and how the body processes it. Participants receive either the drug or a placebo by injection under the skin. The trial is still in early stages, …
Phase 1/2 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New drug cocktail aims to outsmart recurrent glioblastoma
Disease control Recruiting nowThis study tests whether adding the drug selinexor to standard chemotherapy (temozolomide) can better control recurrent glioblastoma, an aggressive brain cancer. About 97 adults whose tumor has returned after initial treatment will receive either the combo or chemotherapy alone. …
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New pill targets Hard-to-Treat cancers with RAS mutations
Disease control Recruiting nowThis study tests an experimental oral drug, BPI-572270, in 120 adults with advanced solid tumors (lung, colorectal, or pancreatic cancer) that have specific RAS gene mutations. The trial has two phases: first to find a safe dose and check for side effects, then to see if the drug…
Phase 1/2 • Sponsor: Betta Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Could a targeted drug boost chemo success in leukemia?
Disease control Recruiting nowThis phase II trial is testing whether adding the drug venetoclax to standard chemotherapy can improve remission rates in younger patients with intermediate-risk acute myeloid leukemia (AML). About 153 participants will receive either standard chemo or a combination with venetocl…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New study to track gene Therapy's Real-World impact on spinal muscular atrophy
Disease control Recruiting nowThis study will follow 36 people with spinal muscular atrophy (SMA) who receive a gene therapy called onasemnogene abeparvovec (ITVISMA) injected into the spinal fluid. The goal is to see how well it works and how safe it is in everyday medical practice. Participants must be at l…
Phase 4 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New drug trial aims to improve lung function in fibrosis patients
Disease control Recruiting nowThis study tests a new medicine called BI 765423 in 71 adults with idiopathic pulmonary fibrosis (IPF), a lung disease that causes scarring and breathing problems. Participants receive either the drug or a placebo by infusion every four weeks for about 3 months. The main goal is …
Phase 2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New drug trial targets rare, aggressive cancer subtype
Disease control Recruiting nowThis phase II trial is testing a drug called puxitatug samrotecan (AZD8205) in 28 adults with an aggressive form of adenoid cystic carcinoma that has spread or come back. The study aims to see if the drug is safe and effective for this specific cancer subtype. Participants will r…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New pill could transform leukemia treatment, phase 3 trial begins
Disease control Recruiting nowThis study tests a new oral drug, QTX-2101, combined with standard ATRA therapy for adults newly diagnosed with a low-risk form of acute promyelocytic leukemia (APL). The goal is to see if the oral capsule works as well as the current intravenous treatment. About 150 participants…
Phase 3 • Sponsor: Quetzal Therapeutics • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New pill plus chemo aims to tackle tough pancreatic cancer
Disease control Recruiting nowThis Phase 3 trial tests whether adding an experimental oral drug called atebimetinib to a modified chemotherapy regimen helps people with metastatic pancreatic cancer live longer. About 510 adults who have not had prior treatment will receive either the new combination or standa…
Phase 3 • Sponsor: Immuneering Corporation • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Boosting transplants with donor immune cells to fight blood cancer relapse
Disease control Recruiting nowThis study tests whether giving donor white blood cells (lymphocytes) soon after a stem cell transplant can lower the chance of cancer returning in people with high-risk blood cancers like leukemia or lymphoma. Participants receive chemotherapy, a stem cell transplant, and then a…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Can doctors watch brain metastases instead of zapping them?
Disease control Recruiting nowResearchers at the University of California, Irvine are testing whether patients with brain metastases can safely skip immediate surgery or radiation and instead have their tumors monitored with regular imaging, cognitive tests, and quality-of-life questionnaires. All participant…
Sponsor: University of California, Irvine • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New pill for duchenne MD enters Mid-Stage trial in young boys
Disease control Recruiting nowThis study tests an oral drug called SAT-3247 in 51 boys aged 7 to 10 with Duchenne muscular dystrophy who can still walk. The goal is to find the best dose, check safety, and see if it helps muscle strength. Participants take the drug or a placebo for 12 weeks, and all continue …
Phase 2 • Sponsor: Satellos Bioscience, Inc. • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New hope for Tough-to-Treat colorectal cancer: phase 3 trial launches
Disease control Recruiting nowThis Phase 3 study tests a new drug, telisotuzumab adizutecan, combined with bevacizumab, against the standard treatment (LONSURF plus bevacizumab) in 700 adults with advanced colorectal cancer that has stopped responding to prior therapies. The goal is to see if the new combo sh…
Phase 3 • Sponsor: AbbVie • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New drug cocktail aims to outsmart advanced cancers
Disease control Recruiting nowThis early-phase trial is testing whether combining the drug talazoparib with one of three other drugs (palbociclib, axitinib, or crizotinib) can safely help control advanced solid tumors that have spread. Talazoparib blocks cancer cells from repairing their DNA, while the other …
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New cocktail of 5 drugs targets tough leukemia
Disease control Recruiting nowThis phase 2 trial is testing a combination of five drugs (fludarabine, cytarabine, filgrastim-sndz, gemtuzumab ozogamicin, and idarubicin) in 270 people with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome that have specific genetic changes. The goal…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Could a diabetes drug boost chemo for tough cancers?
Disease control Recruiting nowThis early-phase trial will test whether adding semaglutide (a GLP-1 drug used for diabetes and weight loss) to standard chemotherapy is safe and tolerable for people with metastatic pancreatic, colorectal, or liver cancer. About 30 participants will receive weekly semaglutide in…
Early phase 1 • Sponsor: University of Arizona • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New hope for Hard-to-Treat lung cancer? osimertinib trial launches
Disease control Recruiting nowThis phase II trial is testing the drug osimertinib in 46 people with advanced non-small cell lung cancer that has a specific genetic change (EGFR exon 20 insertion). The goal is to see if the drug can shrink tumors or slow the cancer's growth. Participants will take osimertinib …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New hope for HIV patients with blood cancer: safer bone marrow transplants on the horizon?
Disease control Recruiting nowThis study tests whether a combination of three drugs (cyclophosphamide, bortezomib, and maraviroc) can safely prevent graft-versus-host disease after a half-matched bone marrow transplant in people living with HIV who also have a blood cancer. The trial involves 265 participants…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New hope for leukemia patients: olverembatinib trial launches
Disease control Recruiting nowThis phase 2 trial tests whether the drug olverembatinib can safely control chronic myeloid leukemia (CML) in people who are newly diagnosed. About 50 adults will take the drug by mouth. Researchers will track side effects and how well the drug works. The study is currently recru…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New drug aims to stop kidney transplant rejection without antibodies
Disease control Recruiting nowThis study tests a drug called felzartamab in people who received a kidney transplant and later developed microvascular inflammation (MVI), a type of injury to small blood vessels in the new kidney that can lead to serious problems. The trial includes 81 participants who will rec…
Phase 2 • Sponsor: Biogen • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New bispecific antibody D3L-002 enters first human trial for Hard-to-Treat cancers
Disease control Recruiting nowThis Phase 1 trial tests D3L-002, a new drug that targets two immune checkpoints (TIGIT and PVRIG) to help the immune system fight cancer. It is for 24 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the r…
Phase 1 • Sponsor: D3 Bio (Wuxi) Co., Ltd • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New blood test and treatment could stop hidden malaria from coming back
Disease control Recruiting nowThis study tests a new way to find and treat a type of malaria (P. vivax) that can hide in the liver and come back months later. Researchers will use a simple blood test to find people who have been infected recently, then give them a treatment to clear the hidden parasites. The …
Phase 3 • Sponsor: London School of Hygiene and Tropical Medicine • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New lung cancer drug ivonescimab takes on pembrolizumab in major trial
Disease control Recruiting nowThis phase 3 study compares ivonescimab, an experimental immunotherapy, to the standard drug pembrolizumab in 780 people with advanced non-small cell lung cancer that has high PD-L1 levels. Participants receive one of the two drugs as their first treatment. The study measures how…
Phase 3 • Sponsor: Summit Therapeutics • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New combo therapy aims to tame kidney disease
Disease control Recruiting nowThis Phase 2 trial tests whether adding belimumab to standard rituximab treatment helps more people with primary membranous nephropathy achieve remission. The study enrolls 58 adults with confirmed disease. Belimumab targets new immune cells, while rituximab depletes existing one…
Phase 2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New study tests Long-Term safety of Cholesterol-Lowering injection for kids
Disease control Recruiting nowThis study looks at the long-term safety of inclisiran, a cholesterol-lowering injection, in children with a genetic condition that causes very high cholesterol. About 195 kids who completed earlier inclisiran studies will receive the drug for an extended period. Researchers will…
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New drug combo targets tough prostate cancer
Disease control Recruiting nowThis study is testing a new drug called ADI-PEG20, which breaks down arginine (a nutrient cancer cells need), together with two chemotherapy drugs (carboplatin and cabazitaxel) in men with aggressive variant prostate cancer. The goal is to find the safest dose and check for side …
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New antibody combo takes on Hard-to-Treat myeloma
Disease control Recruiting nowThis study tests a new antibody drug called HuL001, given together with two standard myeloma drugs (lenalidomide and dexamethasone), in 21 adults whose multiple myeloma has returned or stopped responding to prior treatments. The goal is to see if the combination is safe and can s…
Phase 1/2 • Sponsor: HuniLife Biotechnology, Inc. • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New hope for blood disorder patients: Long-Term safety check for etavopivat
Disease control Recruiting nowThis study looks at the long-term safety and effectiveness of etavopivat, an experimental medicine for sickle cell disease and thalassemia. It involves 480 adults, adolescents, and children who have already benefited from etavopivat in a previous study. Participants will continue…
Phase 3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Lupus drug may shield heart and arteries
Disease control Recruiting nowThis study tests whether anifrolumab, a drug that blocks certain immune signals, can improve blood vessel function and reduce inflammation in people with lupus. About 45 adults with lupus will receive either the drug or a placebo over 8 months. Researchers will measure changes in…
Phase 2 • Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New drug aims to supercharge immune system against prostate cancer
Disease control Recruiting nowThis phase II trial tests whether adding an experimental drug called PDS01ADC to standard radiation and hormone therapy can help the immune system fight prostate cancer. About 65 men with high- or intermediate-risk prostate cancer that hasn't spread will take part. Some will get …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Radiation boost may tame untreatable kidney cancer
Disease control Recruiting nowThis phase II trial tests whether adding precise, high-dose radiation (SABR) to the main kidney tumor improves outcomes for people with metastatic kidney cancer that cannot be surgically removed. Participants receive standard immunotherapy drugs (avelumab, axitinib, or cabozantin…
Phase 2 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New hope for aggressive brain cancer? early trial of ERAS-801 begins
Disease control Recruiting nowThis early-phase trial tests the safety of a drug called ERAS-801 in 10 adults with recurrent glioblastoma, a fast-growing brain cancer. The drug targets a protein called EGFR that is overactive in many of these tumors. Researchers will also check if the drug affects tumor activi…
Phase 1 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New hope for tough colorectal cancer: experimental drug combo enters human testing
Disease control Recruiting nowThis early-phase trial is testing whether adding an experimental drug called ZEN003694 to two approved cancer drugs (cetuximab and encorafenib) can help patients with a specific type of advanced colorectal cancer that has not responded to prior treatments. The study involves 30 a…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Experimental cell therapy takes on tough leukemia
Disease control Recruiting nowThis early-phase trial tests a new treatment called TSLPR-CART for adults with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to treatment. The therapy uses a patient's own immune cells, modified in a lab to target a protein called TSLPR found on …
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Can a new injection help shed pounds? a trial investigates
Disease control Recruiting nowThis clinical trial is testing an experimental drug called ABBV-295 to see if it can help adults with obesity or overweight lose weight. The study will compare different doses of the drug against a placebo (a dummy injection) to measure its effect on body weight over 32 weeks. Pa…
Phase 2 • Sponsor: AbbVie • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New combo therapy aims to boost remission in IDH2-Mutated AML
Disease control Recruiting nowThis phase II trial tests whether adding enasidenib to standard ASTX727 and venetoclax improves remission rates in older adults (or younger unfit patients) with newly diagnosed IDH2-mutated acute myeloid leukemia (AML). About 93 participants will be randomly assigned to receive e…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Can daily adaptive radiotherapy spare healthy tissue in prostate cancer?
Disease control Recruiting nowResearchers are testing whether daily adaptive radiotherapy, which adjusts the radiation plan to each day's anatomy, causes fewer bladder and bowel side effects than standard radiotherapy in people with intermediate or high risk localized prostate cancer. The trial also compares …
Phase 2 • Sponsor: Scott Tyldesley • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New combo therapy aims to tackle rare nasal cancer
Disease control Recruiting nowThis phase 2 trial tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy can shrink advanced squamous cell cancers of the nasal cavity and sinuses better than chemotherapy alone. About 35 adults with newly diagnosed, untreated stage II to IVb disease …
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New cocktail aims to tame tough lymphoma
Disease control Recruiting nowThis study tests a combination of four drugs (mosunetuzumab, polatuzumab, tafasitamab, and lenalidomide) in people with relapsed B-cell non-Hodgkin lymphoma. The goal is to see if this mix can shrink tumors or stop the cancer from growing. About 36 adults who have already tried o…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New combo therapy aims to boost survival in hodgkin lymphoma
Disease control Recruiting nowThis phase 3 trial is testing whether adding immunotherapy drugs (brentuximab vedotin and nivolumab) to standard chemotherapy (with or without radiation) improves survival for people aged 5 to 60 with newly diagnosed stage I or II classical Hodgkin lymphoma. About 1,875 participa…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New antibody AU-007 enters human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called AU-007 in people with advanced solid tumors that have spread or cannot be removed by surgery. The drug is designed to help the immune system fight cancer. About 159 participants will receive AU-007 alone or with other medicines to find the safes…
Phase 1/2 • Sponsor: Aulos Bioscience, Inc. • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New hope for tough prostate cancer: BNT324 takes on chemo
Disease control Recruiting nowThis study tests a new drug called BNT324 against standard chemotherapy (docetaxel) in men with metastatic castration-resistant prostate cancer that has progressed after hormone therapy. The goal is to see if BNT324 helps patients live longer without their cancer worsening. About…
Phase 3 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat cancers with genetic weakness
Disease control Recruiting nowThis early-stage trial is testing a new drug called IDE892, alone or with another drug (IDE397), in people with advanced solid tumors that have a specific genetic deletion (MTAP). The study aims to find safe doses and see if the drugs shrink tumors. It includes 260 adults with ca…
Phase 1 • Sponsor: IDEAYA Biosciences • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New radiation approach before surgery for rare adrenal cancer
Disease control Recruiting nowThis early-phase trial tests giving radiation therapy before surgery to people whose adrenal cancer has come back. The goal is to find a safe radiation dose and see if it helps shrink tumors before removal. About 32 adults with resectable recurrent ACC will receive daily radiatio…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New drug cocktail takes on rare adrenal cancer
Disease control Recruiting nowThis phase II trial tests whether adding the immunotherapy cemiplimab to the targeted drug cabozantinib works better than cabozantinib alone for advanced adrenocortical cancer. About 48 adolescents and adults whose cancer has spread or cannot be removed will take part. The study …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Can donated immune cells calm the cytokine storm?
Disease control Recruiting nowResearchers are testing whether regulatory T cells taken from donated thymus tissue can control the dangerous immune overreaction that occurs in severe COVID-19 and acute respiratory distress syndrome (ARDS). The trial enrolls adults aged 18 to 65 who are hospitalized with acute …
Phase 1/2 • Sponsor: Hospital General Universitario Gregorio Marañon • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New pill hopes to slow rare brain disease in kids
Disease control Recruiting nowThis study tests an oral drug called nizubaglustat in children and teens aged 4 and older with Niemann-Pick type C disease, a rare genetic disorder that affects movement and thinking. Participants will take the drug or a placebo for 18 months to see if it slows the disease and im…
Phase 3 • Sponsor: Azafaros B.V. • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New hope for rare blood cancers: first human trial of PRT12396 begins
Disease control Recruiting nowThis early-stage study tests a new drug, PRT12396, in about 100 people with polycythemia vera or myelofibrosis—rare blood cancers. The main goals are to find a safe dose and check for side effects. Researchers will also look for signs that the drug controls the disease, but this …
Phase 1 • Sponsor: Prelude Therapeutics Incorporated • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New drug DS3610a enters first human tests for Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial is testing a new drug called DS3610a in about 70 adults with advanced or metastatic solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can help control the cancer. P…
Phase 1 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New drug shows promise in slowing spread of aggressive prostate cancer
Disease control Recruiting nowThis study tests whether adding the drug saruparib to standard radiation and hormone therapy can delay the spread of cancer in 700 men with high-risk prostate cancer that has a BRCA gene mutation. Participants will receive either saruparib or a placebo alongside their usual treat…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Can a compound in grapes help Parkinson's? new trial launches
Disease control Recruiting nowThis early-phase trial will test whether a special form of resveratrol (JOTROL) is safe and tolerable for people with Parkinson's disease. About 30 participants will receive either a low dose, high dose, or placebo daily for three months. The study will also measure how the drug …
Phase 2 • Sponsor: Georgetown University • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Could a daily pill replace needles for hemophilia a?
Disease control Recruiting nowThis study tests an experimental oral medicine called Inno8 in 30 adults with hemophilia A. The goal is to see if it is safe and how the body processes it. Participants will take multiple doses over about 11 weeks. If successful, Inno8 could offer a more convenient way to control…
Phase 1 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New pill targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-stage study is testing an experimental oral drug, VVD-133214, in people with advanced solid tumors that have specific genetic features (MSI or dMMR). The drug works by blocking a protein that helps these cancers grow. The study will check safety and how well the drug w…
Phase 1 • Sponsor: Vividion Therapeutics, Inc. • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Can a flexible dosing schedule improve esophageal cancer treatment?
Disease control Recruiting nowThis phase 2 trial is testing whether giving the immunotherapy drug tislelizumab every 2 weeks or every 4 weeks, alongside standard chemotherapy, is safe and effective for Japanese patients with advanced esophageal cancer that cannot be removed by surgery. The study aims to find …
Phase 2 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Sleep pill may shield brain from Alzheimer's damage
Disease control Recruiting nowThis study tests whether the insomnia medication lemborexant (Dayvigo) can lower blood markers of brain damage in adults aged 40–65 with insomnia. Twenty participants will take the drug or a placebo for two weeks each, then have their blood tested for proteins linked to Alzheimer…
Phase 2 • Sponsor: Woolcock Institute of Medical Research • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New hope for rare blood cancers: pacritinib trial opens for teens and adults
Disease control Recruiting nowThis study tests an oral drug called pacritinib in people aged 12 and older with myelodysplastic syndromes (MDS) or related blood cancers (MDS/MPN). The goal is to find the best dose and see if it can shrink or control the disease. Participants take capsules twice daily for up to…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Could a Rose-Scented oil replace standard fillings in Kids' cavities?
Disease control Recruiting nowThis study looks at whether an essential oil from Pelargonium graveolens (a type of geranium) can be used to treat deep cavities in children's baby teeth. The goal is to see if it works as well as current materials to relieve pain and prevent infection. Thirty children will recei…
Sponsor: Tanta University • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Targeted pill takes on rare skull base cancers
Disease control Recruiting nowThis phase 2 trial tests enasidenib, a daily pill that targets the IDH2 gene mutation, in 40 adults with rare cancers of the nasal cavity or skull base that have spread or come back. Participants take the drug once daily in 28-day cycles, and researchers will track how long the c…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New eye drug tiespectus takes on aflibercept in major wet AMD trial
Disease control Recruiting nowThis study tests a new medicine called tiespectus (EYE201) for wet age-related macular degeneration, a leading cause of vision loss. About 960 people will receive either tiespectus or the standard treatment aflibercept via eye injections. The goal is to see if tiespectus can impr…
Phase 2/3 • Sponsor: EyeBiotech Ltd. • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New drug aims to cut blood transfusions for MDS patients
Disease control Recruiting nowThis Phase 3 trial compares elritercept to epoetin alfa in 300 adults with low- to intermediate-risk myelodysplastic syndromes (MDS) who need red blood cell transfusions. The main goal is to see if elritercept can help patients go without transfusions for at least 12 weeks while …
Phase 3 • Sponsor: Takeda • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
One-Shot hope for blinding eye disease? new trial underway
Disease control Recruiting nowThis study tests a single injection into the eye of a new drug (SAR446597) for people with geographic atrophy, a progressive form of age-related macular degeneration that causes vision loss. About 104 participants aged 60 and older will be followed for 2 years, with an optional 3…
Phase 1/2 • Sponsor: Sanofi • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
CRISPR therapy takes aim at stubborn high cholesterol in first human trial
Disease control Recruiting nowThis early-stage trial tests a new CRISPR-based treatment called CTX310 for people with severe cholesterol and triglyceride problems that don't improve with standard therapies. The treatment uses a tiny fat bubble to deliver gene-editing tools that turn off a gene linked to high …
Phase 1 • Sponsor: CRISPR Therapeutics AG • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New pill aims to cut dangerous lung Flare-Ups in bronchiectasis
Disease control Recruiting nowThis study tests a daily pill called BI 1291583 (Verducatib) in 1755 adults and teens with bronchiectasis, a lung condition causing frequent infections and coughing. Participants take either the drug or a placebo for up to 76 weeks. The main goal is to see if the drug reduces the…
Phase 3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New daily pill could ease sickle cell pain for kids
Disease control Recruiting nowThis study tests a once-daily pill called etavopivat in children (6 months to 18 years) with sickle cell disease. The main goals are to check safety and how the drug works in the body, and to see if it can raise hemoglobin levels and reduce painful crises. About 95 children will …
Phase 2 • Sponsor: Forma Therapeutics, Inc. • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Lung cancer vaccine trial aims to stop tumors from coming back
Disease control Recruiting nowThis study tests whether adding an experimental mRNA vaccine (V940) to the immunotherapy drug pembrolizumab (Keytruda) can keep lung cancer from returning after surgery. It includes 680 people with stage II to IIIB non-small cell lung cancer whose tumors did not fully respond to …
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Could detoxing metals boost chemo for leukemia?
Disease control Recruiting nowThis early-stage trial is testing whether two drugs that lower metal levels in the body can help people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) respond better to chemotherapy. The study will enroll 58 adults and aims to find the safest dose and check f…
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Second radiation after surgery or laser therapy shows promise for recurrent brain tumors
Disease control Recruiting nowThis study is for people whose brain metastases have returned after initial radiation. It combines either laser ablation or surgery with a second round of targeted radiation. The goal is to control the disease and monitor side effects in 155 participants.
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New drug mosunetuzumab takes on standard therapy in lymphoma trial
Disease control Recruiting nowThis phase 3 trial tests whether mosunetuzumab works better than rituximab for people with a slow-growing type of lymphoma that has not spread much. Both drugs are lab-made antibodies that help the immune system attack cancer cells. About 600 adults with low tumor burden follicul…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New hope for Tough-to-Treat leukemia: multiple drug cocktails tested
Disease control Recruiting nowThis phase II trial tests several experimental drug combinations against the standard treatment for high-risk acute myeloid leukemia (AML) in patients aged 59 or younger. The goal is to see if newer regimens, including venetoclax and liposome formulations, can better shrink cance…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Fish oil capsules could ease rare muscle disease
Disease control Recruiting nowThis study tests whether omega-3 fatty acid supplements from fish oil, combined with a healthy diet, can reduce disease activity in adults with dermatomyositis, a rare autoimmune disease causing muscle weakness and skin rashes. About 300 participants will take either fish oil cap…
Phase 2 • Sponsor: National Institute of Environmental Health Sciences (NIEHS) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New cell therapy GT719 targets tough blood cancers in early trial
Disease control Recruiting nowThis early-phase trial is testing an experimental cell therapy called GT719 in 46 adults with relapsed or treatment-resistant B-cell lymphoma or leukemia that tests positive for CD19. The study aims to see if the treatment is safe and how well it works. Participants receive a sin…
Phase 1/2 • Sponsor: Grit Biotechnology • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New hope for advanced penile cancer: drug combo targets tough cases
Disease control Recruiting nowThis study tests a new combination of two drugs (becotatug vedotin and pucotenlimab) in 20 adults with advanced penile cancer that has spread and is EGFR-positive. Participants must have failed or be unable to tolerate chemotherapy. The goal is to see if the treatment can shrink …
Phase 2 • Sponsor: Fudan University • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Triple threat: new combo aims to tackle Hard-to-Treat prostate cancer
Disease control Recruiting nowThis study tests a new drug, AMO959, combined with a targeted radiation therapy (Pluvicto) and a hormone therapy in men with a specific type of advanced prostate cancer (PSMA-positive mCRPC) that has stopped responding to prior hormone treatment. The trial has two phases: first t…
Phase 1/2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Scientists train immune cells to hunt down mutated blood cancers
Disease control Recruiting nowThis early-phase trial tests a personalized treatment for people with blood cancers like leukemia. Doctors take a patient's own T cells, modify them in the lab to recognize unique cancer mutations, and infuse them back after a short course of chemotherapy. The goal is to see if t…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Could a simpler HIV pill protect moms and babies?
Disease control Recruiting nowThis study will test a two-drug HIV pill (Dolutegravir/Lamivudine) in 210 pregnant women who have never taken HIV medication. The goal is to see if it controls the virus and prevents passing HIV to their babies. Participants will be compared to those on standard three-drug therap…
Phase 4 • Sponsor: Fundación Huésped • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New drug combo aims to shrink HER2-Positive tumors
Disease control Recruiting nowThis study tests whether adding palbociclib to neratinib works better than neratinib alone for people with HER2-positive solid tumors (excluding breast cancer). Both drugs block signals that help cancer cells grow. The trial enrolls 70 adults with advanced or recurrent gynecologi…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New combo aims to stop early breast cancer in its tracks
Disease control Recruiting nowThis phase 3 trial is testing whether adding the targeted drug ribociclib to standard hormone therapy can help prevent invasive breast cancer from returning in people with HR+ HER2- early breast cancer. About 1,400 participants will receive the combination for up to 3 years. The …
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Can a cementless hip stem hold up in asian patients?
Disease control Recruiting nowResearchers at a Korean hospital are following 210 adults who receive a cementless total hip replacement using the collarless Actis femoral stem. The study focuses on Asian patients, who tend to be younger at surgery and more often need the operation because of lost blood supply …
Sponsor: Seoul National University Bundang Hospital • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New hope for Tough-to-Treat lymphoma: Two-Drug combo enters Mid-Stage trial
Disease control Recruiting nowThis Phase 2 trial is testing a new drug called MEN1703, both alone and combined with another drug called glofitamab, in 178 adults with aggressive B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior treatments. The study aims to see if the drugs…
Phase 2 • Sponsor: Ryvu Therapeutics SA • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New hope for kidney patients: experimental drug takes on standard therapy
Disease control Recruiting nowThis study tests a new drug, povetacicept, against a standard treatment (calcineurin inhibitor) in 176 adults with primary membranous nephropathy, a kidney disease that can lead to kidney failure. The goal is to see if the new drug can put the disease into remission more safely a…
Phase 2/3 • Sponsor: Vertex Pharmaceuticals Incorporated • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New drug combo aims to halt blinding eye disease
Disease control Recruiting nowThis phase 3 trial tests two injectable drugs, pozelimab and cemdisiran, alone or together, to slow the growth of geographic atrophy—an advanced form of dry age-related macular degeneration that causes central vision loss. About 975 participants will receive either the drugs or a…
Phase 3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Brain pacemaker trial aims to tame Parkinson's symptoms
Disease control Recruiting nowThis study follows 300 adults with Parkinson's disease, essential tremor, or dystonia who receive deep brain stimulation (DBS). DBS uses a device implanted in the chest to send electrical pulses to brain areas controlling movement. Researchers will track symptom severity, medicat…
Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Could cutting back on IV fluids save lives in septic shock?
Disease control Recruiting nowThis study is testing whether giving fewer non-essential fluids to adults with septic shock can improve outcomes. The trial will enroll 1,850 patients in intensive care, comparing a restrictive fluid strategy to usual care. The main goal is to see if this approach reduces deaths …
Sponsor: Region Skane • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New combo therapy aims to stop High-Risk breast cancer from coming back
Disease control Recruiting nowThis phase III trial is testing whether adding the immunotherapy drug durvalumab to standard chemotherapy can prevent breast cancer from returning in people with a specific high-risk type of hormone receptor-positive, HER2-negative breast cancer. About 3,680 participants with sta…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New combo pill aims to shrink spleens and ease symptoms in bone marrow cancer
Disease control Recruiting nowThis phase 3 trial tests whether adding pelabresib to the standard drug ruxolitinib works better than ruxolitinib alone for people with myelofibrosis, a type of bone marrow cancer. About 460 adults who have not taken JAK inhibitors before will receive either the combination or a …
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Can a Gene-Silencing drug tame a rare heart disease?
Disease control Recruiting nowThis trial tests an investigational medicine called ATR 1072 in adults with PRKAG2 syndrome, a genetic condition that causes abnormal heart muscle thickening and rhythm problems. The drug is designed to reduce the activity of the faulty PRKAG2 gene. Researchers are evaluating its…
Phase 1/2 • Sponsor: Atrium Therapeutics • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Can a donor stem cell transplant fix broken immune systems?
Disease control Recruiting nowThis study tests whether a stem cell transplant from a healthy donor can help people with severe primary immunodeficiencies. Participants aged 4 to 75 receive chemotherapy before the transplant to prepare their body. The goal is to see if the procedure is safe and can improve imm…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New cancer drug YL217 enters first human tests
Disease control Recruiting nowThis early-phase study is testing an experimental drug called YL217 in 220 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and look for early signs that the drug can shrink tumors. Participa…
Phase 1 • Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New hope for ALK lung cancer: first human trial of AQUA07 begins
Disease control Recruiting nowThis early-stage trial tests a new oral drug called AQUA07, alone or with another drug (lorlatinib), in about 102 people with ALK-positive non-small cell lung cancer that has spread or cannot be removed. The main goals are to check safety, find the right dose, and see how the bod…
Phase 1 • Sponsor: Chugai Pharmaceutical • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Prison program aims to alert partners of HIV risk
Disease control Recruiting nowThis study tests whether a program that helps incarcerated men with HIV notify their sex and drug-use partners about possible HIV exposure can increase testing and treatment. Participants can choose to tell partners themselves or have a trained notifier do it anonymously. The goa…
Sponsor: University of Illinois at Chicago • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New combo therapy aims to shrink lung tumors without chemo or surgery
Disease control Recruiting nowThis study tests a drug called NBTXR3 given with radiation therapy for people with locally-advanced non-small cell lung cancer who cannot have chemotherapy or surgery. The goal is to see if the combination is safe and helps control the cancer. About 40 adults with stage I to III …
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Brain cancer breakthrough? GammaTile trial aims to boost survival
Disease control Recruiting nowThis Phase 3 trial tests whether adding a special radiation tile (GammaTile) during brain surgery improves survival for people with newly diagnosed glioblastoma, a fast-growing brain cancer. About 766 participants will be randomly assigned to standard treatment (surgery, radiatio…
Phase 3 • Sponsor: GT Medical Technologies, Inc. • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New drug combo aims to tackle bipolar depression and suicidal thoughts
Disease control Expanded accessThis study offers NRX-101, a combination of two drugs, to adults aged 18-65 with treatment-resistant bipolar depression and suicidal thoughts. Participants receive the medication from their own psychiatrist and undergo regular check-ins on mood, suicidal ideation, and side effect…
Sponsor: NeuroRx, Inc. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New hope for pancreatic cancer: targeted drug may delay return in BRCA patients
Disease control Recruiting nowThis phase II trial is testing whether the drug olaparib can help prevent pancreatic cancer from coming back in people who have already had surgery and chemotherapy and carry a BRCA1, BRCA2, or PALB2 mutation. Olaparib is a targeted therapy that blocks a repair enzyme cancer cell…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Keytruda's Long-Term safety under the microscope in massive cancer trial
Disease control Recruiting nowThis study is checking the long-term safety and effectiveness of the cancer drug pembrolizumab (Keytruda) in 3500 people with various solid tumors or blood cancers. Participants are moving from earlier Merck studies into this one, continuing their treatment or follow-up. The goal…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New drug targets Hard-to-Treat cancers with genetic weakness
Disease control Recruiting nowThis study tests a new drug, TER-2013, in people with advanced solid tumors (like breast, ovarian, or lung cancer) that have specific genetic changes in the AKT/PI3K/PTEN pathway. The goal is to see if the drug is safe and can shrink tumors. About 205 participants will receive th…
Phase 1/2 • Sponsor: Terremoto Biosciences Inc. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New hope for advanced cancer: experimental drug targets Hard-to-Treat tumors
Disease control Recruiting nowThis early-phase study is testing an experimental drug called 177Lu-IM-3050 in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety and find the best dose. About 105 participants will receive the drug to s…
Phase 1 • Sponsor: Immunome, Inc. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Can a new drug ease the joint pain of psoriatic arthritis?
Disease control Recruiting nowThis trial tests an experimental drug called DDY391 in about 220 adults with moderate to severe psoriatic arthritis, a condition that causes joint pain, swelling, and skin patches. Researchers want to see whether DDY391 can reduce joint symptoms better than a placebo and at what …
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Two-Drug combo targets prostate cancer that outsmarts hormone therapy
Disease control Recruiting nowResearchers are testing a combination of two experimental drugs, JANX013 and JANX007, in men with metastatic castration-resistant prostate cancer, an advanced form that keeps growing despite hormone-lowering treatment. The Phase 1 trial gives both drugs by intravenous infusion to…
Phase 1 • Sponsor: Janux Therapeutics • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Could your own bone marrow cells save your hip from collapse?
Disease control Recruiting nowThis study tests whether adding a patient's own concentrated bone marrow cells to a standard hip surgery (core decompression) can prevent the hip ball from collapsing and delay or avoid the need for a hip replacement. It includes 192 adults with early-stage osteonecrosis (before …
Sponsor: Johns Hopkins University • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Special lenses may curb worsening eyesight in children
Disease control Recruiting nowThis study tests two types of modified spectacle lenses designed to slow the progression of myopia (nearsightedness) in children aged 6 to 13. Over one year, researchers will measure changes in the back of the eye (choroid), eye length, and prescription strength. The goal is to s…
Sponsor: The Hong Kong Polytechnic University • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Promising new combo aims to beat aggressive leukemia
Disease control Recruiting nowThis phase 2 trial is testing a combination of blinatumomab (an immune-boosting drug) with dasatinib or imatinib (targeted pills) and standard chemotherapy for people with a specific type of leukemia called Philadelphia chromosome-positive or Philadelphia chromosome-like B-ALL. T…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New drug combo aims to outperform standard care in aggressive lung cancer
Disease control Recruiting nowThis Phase 3 trial will test whether a new drug called BL-M14D1 combined with atezolizumab works better than the current standard treatment for people with extensive-stage small cell lung cancer who have not had prior therapy. About 550 adults will be randomly assigned to receive…
Phase 3 • Sponsor: SystImmune Inc. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Experimental drug combo aims to extend cancer control in lung cancer
Disease control Recruiting nowThis trial tests whether adding the experimental drug iadademstat to standard immunotherapy (atezolizumab or durvalumab) can help keep extensive-stage small cell lung cancer from growing. About 45 adults whose cancer responded to initial chemo-immunotherapy will receive the combi…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Can a lung cancer drug work against other rare neuroendocrine tumors?
Disease control Recruiting nowResearchers are testing tarlatamab in people with advanced extrapulmonary small cell carcinoma or neuroendocrine carcinoma that has worsened after platinum-based chemotherapy. These rare cancers often carry high levels of a protein called DLL3, which tarlatamab targets by linking…
Phase 2 • Sponsor: National Taiwan University Hospital • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New hope for kids with colitis: risankizumab trial launches
Disease control Recruiting nowThis phase 3 study tests the drug risankizumab in about 120 children aged 2 to 18 with moderate to severe ulcerative colitis. The trial has three parts: an initial 12-week IV treatment period, a 52-week maintenance phase where patients get one of two doses by injection, and a lon…
Phase 3 • Sponsor: AbbVie • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New antibody combo shows promise for Hard-to-Treat myeloma
Disease control Recruiting nowThis early-phase trial is testing an experimental antibody called cevostamab, either alone or combined with other drugs (pomalidomide, daratumumab, and dexamethasone), in 126 people with multiple myeloma that has returned or stopped responding to treatment. The main goals are to …
Phase 1 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New hope for Tough-to-Treat blood cancers: NX-5948 trial opens
Disease control Recruiting nowThis study tests an experimental drug called NX-5948 in adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or not responded to prior treatments, including BTK and BCL-2 inhibitors. The main goal is to see if the drug can shrink o…
Phase 2 • Sponsor: Nurix Therapeutics, Inc. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Biomarker-Guided combo aims to outsmart tough cancers
Disease control Recruiting nowThis phase II trial is testing whether the combination of cabozantinib (a targeted therapy) and nivolumab (an immunotherapy) can shrink or stabilize advanced melanoma and head and neck cancers that have stopped responding to prior immunotherapy. Researchers are also checking if t…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Engineered immune cells take on muscle disease
Disease control Recruiting nowThis study tests a one-time treatment called CABA-201, made from a patient's own immune cells, for people with active inflammatory muscle diseases like dermatomyositis. The therapy aims to reset the immune system by targeting and removing certain immune cells. Researchers will ch…
Phase 2/3 • Sponsor: Cabaletta Bio • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New combo therapy aims to tackle breast cancer brain metastases
Disease control Recruiting nowThis study is testing whether combining a targeted drug (abemaciclib) with precise radiation (stereotactic radiosurgery) can better control brain tumors in people with a common type of breast cancer (HR+/HER2-). About 31 participants will receive both treatments along with hormon…
Phase 1/2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Can a simple shot replace an IV for this aggressive lung cancer?
Disease control Recruiting nowThis phase 3 trial is testing whether tarlatamab, an immunotherapy drug, can be given as a quick injection under the skin instead of a slow intravenous drip for people with relapsed extensive-stage small cell lung cancer. The study will compare the two methods to see if the injec…
Phase 3 • Sponsor: Amgen • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Can a blast of testosterone shrink hard-to-treat prostate cancer?
Disease control Recruiting nowThis trial investigates whether high doses of testosterone can shrink tumors in men with metastatic prostate cancer that no longer responds to standard hormone therapy and has mutations in DNA repair genes like ATM or CDK12. Participants receive monthly injections of high-dose te…
Phase 2 • Sponsor: VA Office of Research and Development • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New hope for kids with tough cancers: targeted radiation trial launches
Disease control Recruiting nowThis early-stage trial tests a radioactive drug (Lu-177 edotreotide) in children aged 2 to 17 with cancers that have a specific marker (SSTR-positive). The goal is to find the right dose and check safety. About 20 children whose cancer has returned or not responded to prior treat…
Phase 1 • Sponsor: ITM Solucin GmbH • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Precision radiation may tame prostate cancer with fewer side effects
Disease control Recruiting nowThis phase II trial is testing a focused, high-dose radiation therapy (SBRT) given in just two sessions for men with early-stage prostate cancer that hasn't spread. The goal is to see if this approach can destroy the tumor while avoiding the side effects of treating the whole pro…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Two-Drug combo aims to stall advanced breast cancer
Disease control Recruiting nowResearchers are testing whether dalpiciclib, a targeted cancer drug, combined with toremifene, a hormonal therapy, can slow the growth of advanced HR-positive, HER2-negative breast cancer when used as a first-line treatment. The trial plans to enroll 36 women who have not yet rec…
Phase 2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New pill targets Hard-to-Treat lung cancer mutation
Disease control Recruiting nowThis trial tests an experimental daily pill, VS-7375, for people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12D. Participants must have already tried chemotherapy and an immunotherapy drug. The study looks at whether the drug can shri…
Phase 2 • Sponsor: Verastem, Inc. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Radioactive One-Two punch takes on returning prostate cancer
Disease control Recruiting nowThis phase II trial is testing two radioactive drugs, 225Ac-PSMA-617 and 177Lu-PSMA-617, combined with precise radiation therapy for prostate cancer that has returned and spread to a few spots in the body. The drugs target a protein on cancer cells and deliver radiation to kill t…
Phase 2 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Could a cancer drug ease rett syndrome? early trial launches
Disease control Recruiting nowThis early-stage trial is testing the drug vorinostat in 15 girls and young women with Rett syndrome, a rare genetic disorder that affects brain development. Each participant will receive placebo and two different doses of vorinostat, acting as their own control. The study aims t…
Phase 1 • Sponsor: Unravel Biosciences, Inc. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New combo aims to boost transplant success in rare blood cancer
Disease control Recruiting nowThis study tests whether giving a chemotherapy drug (decitabine) plus a targeted therapy (ruxolitinib, fedratinib, or pacritinib) before a stem cell transplant helps people with advanced myeloproliferative neoplasms (MPN) get to transplant and have better outcomes. About 25 adult…
Phase 2 • Sponsor: University of Washington • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Can a pill target tumors with the PIK3CA-H1047R mutation?
Disease control Recruiting nowResearchers are testing an experimental oral drug called REC-7735 in adults with advanced solid tumors that carry a specific change in the PIK3CA gene, known as H1047R. The trial enrolls about 90 participants whose cancer cannot be removed by surgery or has spread, and who have a…
Phase 1/2 • Sponsor: Recursion Pharmaceuticals Inc. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Five-Fraction radiation plus hormone therapy tested against High-Risk prostate cancer
Disease control Recruiting nowResearchers are testing a treatment plan for men with high-risk localized prostate cancer that combines whole-pelvis radiation given in five sessions, a high-dose radiation boost directly to the prostate, and two years of androgen deprivation therapy. The study aims to see how of…
Phase 2 • Sponsor: German Oncology Center, Cyprus • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Triple threat: immunotherapy, chemo, and radiation take on rectal cancer
Disease control Recruiting nowThis phase 2 trial is testing whether adding an immunotherapy drug (adebrelimab) to a chemotherapy combo (NALIRIFOX) and radiation can improve outcomes for people with a certain type of locally advanced rectal cancer (pMMR/MSS). About 84 participants will be randomly assigned to …
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New contact lenses aim to curb childhood myopia epidemic
Disease control Recruiting nowThis study tests two types of daily disposable contact lenses designed to slow the progression of myopia (nearsightedness) in children aged 7 to 12. Over two years, 126 Hong Kong Chinese children will wear either a special lens or a standard single-vision lens, with their eyes me…
Sponsor: The Hong Kong Polytechnic University • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Can a tailored diet boost brain and body health in denture-wearers?
Disease control Recruiting nowThis study tests a 6-month nutritional program for adults aged 60–80 who wear complete dentures. Participants receive personalized dietary advice, meal plans, cooking workshops, and a mobile app. The goal is to see if the program improves diet quality, chewing ability, muscle str…
Sponsor: Universidad de La Frontera • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Chemo combo tested as backup for bladder cancer that outsmarts First-Line therapy
Disease control Recruiting nowResearchers are testing whether a chemotherapy combination called gemcitabine and carboplatin can help people with advanced urothelial cancer whose disease has worsened after treatment with enfortumab vedotin and pembrolizumab. The trial enrolls about 55 participants who receive …
Phase 2 • Sponsor: Fox Chase Cancer Center • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Immune boosters take on brain cancer: new trial launches
Disease control Recruiting nowThis phase 2 trial tests two immunotherapy drugs, nivolumab and relatlimab, in people with newly diagnosed glioblastoma, a fast-growing brain cancer. About 92 participants will receive the drugs before and after surgery to see if they are safe and help the immune system attack th…
Phase 2 • Sponsor: Duke University • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Should High-Risk CLL patients start treatment early? major trial aims to find out
Disease control Recruiting nowThis phase 3 trial compares starting treatment with venetoclax and obinutuzumab right away versus waiting until symptoms appear in people with newly diagnosed, high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma. About 247 participants will be randomly assigned t…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Can turbocharged immune cells stop liver cancer from coming back?
Disease control Recruiting nowResearchers are testing whether combining microwave ablation with infusions of a patient's own expanded immune cells helps people with small liver tumors. The trial enrolls adults with up to three tumors, each no larger than 5 cm, who are not eligible for surgery. After ablation,…
Phase 2/3 • Sponsor: Chinese PLA General Hospital • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New chemo formula aims to keep lung cancer away after surgery
Disease control Recruiting nowThis study tests a drug called SMS001, a new version of the chemotherapy paclitaxel, in 42 people with non-small cell lung cancer (stages Ib to IIIa). The goal is to see if a single dose after surgery can safely prevent the cancer from coming back. Researchers will monitor side e…
Phase 2 • Sponsor: ToLymph Inc. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Can a new pill keep High-Risk COVID-19 patients out of the hospital?
Disease control Recruiting nowThis phase 3 trial is testing whether the oral antiviral secutrelvir can prevent severe COVID-19 in people who are at high risk for complications. Participants with mild symptoms and confirmed SARS-CoV-2 infection will receive either secutrelvir or a placebo. The study will measu…
Phase 3 • Sponsor: Shionogi • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New hope for tough leukemia: MK-1045 takes on standard therapy
Disease control Recruiting nowThis study compares a new immunotherapy, MK-1045, to the standard drug blinatumomab in people whose B-cell acute lymphoblastic leukemia has returned or stopped responding to treatment. About 340 adults with CD19-positive leukemia will receive one of the two treatments. The goal i…
Phase 2/3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New shot aims to help kids with rare heart-muscle disease move easier
Disease control Recruiting nowThis study tests a daily injection called elamipretide in 48 people with genetically confirmed Barth syndrome, a rare condition that causes muscle weakness and heart problems. Participants will receive either the drug or a placebo for 72 weeks. The main goal is to see if the drug…
Phase 4 • Sponsor: Stealth BioTherapeutics Inc. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Will lifting weights save muscle while losing weight?
Disease control Recruiting nowThis trial tests whether adding resistance training (like weight lifting) to the weight-loss drug tirzepatide helps preserve thigh muscle in adults with obesity. Participants will receive tirzepatide and either a structured exercise program or usual care. The main goal is to see …
Phase 4 • Sponsor: Technical University of Munich • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New hope for multiple myeloma: phase 3 trial launches
Disease control Recruiting nowThis Phase 3 trial tests a new drug called IBI3003 against standard treatments for people with multiple myeloma that has returned or is not responding to therapy. About 255 participants will be randomly assigned to receive either IBI3003 or a standard treatment chosen by their do…
Phase 3 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New hope for Triple-Negative breast cancer: combo aims to stop recurrence
Disease control Recruiting nowThis phase 3 trial tests whether adding the experimental drug sacituzumab tirumotecan (MK-2870) to the immunotherapy pembrolizumab can better prevent breast cancer from coming back in people with triple-negative breast cancer who still had tumor after initial treatment. About 1,5…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Engineered t cells target hidden leukemia cells in new trial
Disease control Recruiting nowThis phase I trial tests a new treatment for adults with acute myeloid leukemia (AML) who have minimal residual disease (MRD) — small amounts of cancer cells that remain after standard therapy. The treatment uses the patient's own T cells, genetically modified to recognize a prot…
Phase 1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New drug combo aims to keep ovarian cancer at bay
Disease control Recruiting nowThis Phase 3 trial tests whether a targeted therapy called sacituzumab tirumotecan (Sac-TMT), given alone or with bevacizumab, can help people with advanced ovarian cancer live longer without their cancer growing. About 900 participants who have finished initial chemotherapy will…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New combo therapy targets hard-to-treat breast cancers
Disease control Recruiting nowThis study tests two experimental drugs, BNT323 and BNT327, together in people with advanced breast cancer that has spread or cannot be removed. The goal is to see if the combination can shrink tumors and control the disease. About 380 adults with various types of breast cancer (…
Phase 1/2 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Can two immunotherapy drugs make liver tumors more vulnerable to surgery?
Disease control Recruiting nowResearchers are testing whether adding two immunotherapy drugs, durvalumab and tremelimumab, to focused radiation before surgery changes the immune cell makeup inside liver tumors. The trial enrolls 30 people with a single liver tumor that can be removed surgically. Everyone rece…
Phase 3 • Sponsor: Hamilton Health Sciences Corporation • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Experimental drug velzatinib offered to GIST patients who have run out of options
Disease control Expanded accessThis expanded access program provides velzatinib (GSK6042981) to patients with gastrointestinal stromal tumors (GIST) that have a KIT mutation and have already tried at least three prior treatments. The program is for people who have no satisfactory alternative, including approve…
Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Engineered immune cells take on rare solid tumors in first human trial
Disease control Recruiting nowThis early-phase study tests a new treatment called GCAR1, which uses a patient's own immune cells (T-cells) that have been modified to recognize and attack cancer cells carrying a specific marker (GPNMB). The study enrolls 30 adults in Canada with advanced alveolar soft part sar…
Phase 1 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New antibody tested to tame childhood arthritis and cut steroid use
Disease control Recruiting nowResearchers are testing an experimental drug called GenaKumab in children and teens with active systemic juvenile idiopathic arthritis, a condition that causes joint inflammation and recurring fevers. The trial enrolls about 290 participants aged 2 to under 18 who have had sympto…
Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Experimental drug plus radiation shows promise for rare sarcoma
Disease control Recruiting nowThis early-phase trial is testing whether the drug abemaciclib, when given with radiation therapy before surgery, can safely shrink high-risk retroperitoneal liposarcomas. About 18 adults with this rare cancer will receive the combination to find the best dose and check for side …
Phase 1 • Sponsor: University of Washington • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
A pill to stop the bleeding? new hope for HHT nosebleeds
Disease control Recruiting nowThis phase 3 trial tests whether an experimental oral drug called engasertib can reduce the number of nosebleeds in adults with moderate to severe hereditary hemorrhagic telangiectasia (HHT), a genetic condition that causes abnormal blood vessels and frequent bleeding. About 240 …
Phase 3 • Sponsor: Vaderis Therapeutics AG • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Could an immune booster keep early lung cancer from returning?
Disease control Recruiting nowThis phase 3 trial is testing whether the immunotherapy drug durvalumab, given after surgery, can prevent early-stage non-small cell lung cancer from coming back. About 306 participants who have had their tumor completely removed will be randomly assigned to receive durvalumab or…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New Antibody-Drug combo aims to tackle tough lymphoma
Disease control Recruiting nowThis study tests whether adding the experimental drug zilovertamab vedotin to standard chemotherapy helps people with diffuse large B-cell lymphoma that has come back or not responded to treatment. About 290 adults will be randomly assigned to receive either the new combination o…
Phase 2/3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Smart bombs for lung cancer: new ADC drugs enter trial
Disease control Recruiting nowThis phase 2 trial tests two antibody-drug conjugates (ADCs) — R-DXD and I-DXD — against standard chemotherapy in 144 people with advanced squamous non-small cell lung cancer that has worsened after initial treatment. ADCs are like guided missiles that deliver a cancer-killing dr…
Phase 2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Experimental drug HDP-101 targets Hard-to-Treat myeloma
Disease control Recruiting nowThis study tests an experimental drug, HDP-101, in people with multiple myeloma or related plasma cell disorders. The goal is to see if the drug is safe and can shrink tumors. Participants have already tried other treatments, including stem cell transplant or are not eligible for…
Phase 1/2 • Sponsor: Heidelberg Pharma AG • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Precision radiotherapy may buy time for men with spreading prostate cancer
Disease control Recruiting nowThis study investigates whether precisely targeted radiotherapy can delay the need for stronger drugs in men with prostate cancer that has started to grow in a few new spots while on systemic therapy. Participants have metastatic hormone-sensitive or castration-resistant prostate…
Sponsor: Affidea Nu-med Center of Oncological DIagnostics and Therapy • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New pill aims to tackle Huntington's at its source
Disease control Recruiting nowThis clinical trial tests an oral drug called SKY-0515 in 400 adults with Huntington's disease. The goal is to see if it can lower harmful proteins linked to the disease and improve symptoms like movement and thinking. Participants take the drug or a placebo daily for 18 months.
Phase 2/3 • Sponsor: Skyhawk Therapeutics, Inc. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New drug combo takes on Hard-to-Treat prostate cancer
Disease control Recruiting nowThis study tests a new drug called ifinatamab deruxtecan (I-DXd), given alone or with other treatments, in men with metastatic castration-resistant prostate cancer (mCRPC) that has worsened despite hormone therapy. The trial aims to find safe doses and see if the drug can lower P…
Phase 1/2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New combo therapy aims to extend life in advanced lung cancer
Disease control Recruiting nowThis phase 3 trial tests whether adding the experimental drug MK-2870 to the standard immunotherapy pembrolizumab helps people with advanced non-small cell lung cancer live longer compared to pembrolizumab alone. The study enrolls about 614 adults whose tumors have high PD-L1 lev…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New drug may help stem cell transplant patients avoid extra immune suppression
Disease control Recruiting nowThis study tests whether the drug belumosudil can prevent chronic graft-versus-host disease (cGVHD) from worsening in stem cell transplant recipients. About 82 participants will receive either belumosudil or a placebo. The goal is to see if the drug delays the need for additional…
Phase 2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New hope for Crohn's? large trial tests tulisokibart
Disease control Recruiting nowThis phase 3 trial is testing a drug called tulisokibart in about 1,200 people with moderate-to-severe Crohn's disease who haven't had success with other treatments. The drug is given by IV or injection and aims to reduce symptoms and heal the gut lining. The study compares tulis…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New pill aims to slow kidney damage in FSGS patients
Disease control Recruiting nowThis study tests an oral medication called BI 764198 for people with a kidney condition called focal segmental glomerulosclerosis (FSGS). About 286 adults and teens will take either the study drug or a placebo daily for up to 2 years, while continuing their usual FSGS treatments.…
Phase 3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New hope for colorectal cancer in nigeria: immunotherapy trial launches
Disease control Recruiting nowThis study tests a drug called tislelizumab for people in Nigeria with a specific type of colorectal cancer (mismatch repair deficient). The drug helps the immune system attack cancer cells. The study will check if the drug shrinks tumors and is safe. It includes 40 adults who ha…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New hope for advanced kidney cancer: experimental drug enters human trials
Disease control Recruiting nowThis study tests a new medicine, PF-08634404, in adults with advanced kidney cancer that has spread. The goal is to see if the drug is safe and can shrink tumors when used alone or with other cancer drugs. About 224 participants who have not had prior treatment for their advanced…
Phase 1/2 • Sponsor: Pfizer • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
A supplement aims to fill the gap after GLP-1 weight-loss drugs
Disease control Recruiting nowThis trial tests whether elénzia CONTROL®, a dietary supplement, can support weight management in adults who have either never used GLP-1 weight-loss medications or recently stopped them. Participants take two capsules daily for 16 weeks, and researchers compare weight changes ag…
Sponsor: Elenzia • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Gut check: probiotic may sharpen memory and tame blood sugar in prediabetes
Disease control Recruiting nowThis study tests whether taking a daily probiotic (Lab4P) for 12 weeks can improve memory, thinking speed, and blood sugar control in overweight adults aged 18-40 with prediabetes (mildly high blood sugar). Seventy participants will be randomly assigned to receive either the prob…
Sponsor: Leeds Beckett University • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New Triple-Drug attack on cervical cancer enters final testing
Disease control Recruiting nowThis phase 3 trial tests whether adding the experimental drug sacituzumab tirumotecan (sac-TMT) to standard immunotherapy (pembrolizumab) and a targeted therapy (bevacizumab) helps people with metastatic cervical cancer live longer. About 1,000 participants whose cancer has sprea…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Promising new treatment for rare Muscle-Weakening disease enters human trials
Disease control Recruiting nowThis study tests a drug called ublituximab for people with a rare autoimmune disease that causes severe muscle weakness. The goal is to see if adding this drug to standard treatment improves muscle strength and function more than standard treatment alone. About 30 adults with ear…
Phase 2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Can weekly Finger-Prick tests improve PKU control?
Disease control Recruiting nowResearchers are testing whether measuring phenylalanine at home once a week, rather than once a month, helps adults with classic phenylketonuria keep their levels in a healthier range. The trial enrolls 36 adults aged 18 to 65 who follow a low-protein diet and use special amino a…
Sponsor: Michał Kania • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New cocktail aims to shrink pancreatic tumors before surgery
Disease control Recruiting nowThis phase 2 trial tests whether giving a powerful chemotherapy regimen called NALIRIFOX along with targeted radiation and the drug capecitabine can shrink pancreatic tumors enough to allow successful surgery. The study enrolls 60 people with borderline resectable or locally adva…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Gut bacteria trial aims to slow ALS and dementia
Disease control Recruiting nowThis study tests whether a special probiotic supplement can change fat-related molecules in the blood of people with ALS and frontotemporal dementia (FTD). Researchers will compare those taking the probiotic to those taking a placebo over 24 weeks. The goal is to see if the probi…
Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New drug targets Hard-to-Treat cancers in large trial
Disease control Recruiting nowThis phase 2 trial is testing an experimental drug called patritumab deruxtecan (HER3-DXd) in 740 people with advanced solid tumors, including melanoma, lung, breast, and other cancers. The drug is given by IV every three weeks. The main goal is to see if the drug shrinks tumors.…
Phase 2 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
3D printed dentures face off against traditional milled ones in new trial
Disease control Recruiting nowThis study compares two types of full dentures: 3D printed ones and milled ones. Researchers want to see which lasts longer and causes fewer problems over five years. Sixty-eight adults who need complete dentures will take part, and the main focus is how many dentures are still w…
Sponsor: Dentsply Sirona Implants and Consumables • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New drug cocktail targets Virus-Linked cancers in early trial
Disease control Recruiting nowThis phase 1 study tests a combination of two drugs, pomalidomide (a pill) and nivolumab (an infusion), in adults with cancers caused by viruses like Epstein-Barr, HPV, or hepatitis. The goal is to find a safe dose and see if the drugs can shrink tumors. Up to 58 people with Kapo…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New pill aims to keep HER2 lung cancer from returning after surgery
Disease control Recruiting nowThis study tests whether a daily pill called zongertinib can help prevent lung cancer from coming back in people with early-stage (Stage II-IIIB) non-small cell lung cancer that has a specific HER2 mutation. All participants have had surgery to remove their tumor and standard che…
Phase 3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Triple-Drug cholesterol attack aims to strike within 72 hours of a heart attack
Disease control Recruiting nowResearchers are testing whether adding bempedoic acid to high-intensity statin and ezetimibe therapy within 72 hours after a heart procedure helps adults with acute coronary syndrome reach very low LDL cholesterol. Participants receive either the three-drug combination or the sta…
Phase 4 • Sponsor: Taipei Medical University Hospital • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New cocktail of drugs takes on Hard-to-Treat bladder cancer
Disease control Recruiting nowThis early-phase trial tests a combination of three drugs—enfortumab vedotin, pembrolizumab, and quemliclustat—in people with advanced bladder or urinary tract cancer that has spread or cannot be removed by surgery. The goal is to see if the combination is safe and effective. The…
Phase 1/2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New Antibody-Drug conjugate IM-1617 enters human trials for advanced cancers
Disease control Recruiting nowThis early-stage trial is testing a new drug called IM-1617 in people with advanced solid tumors (cancers that have spread or can't be removed by surgery). The study has two parts: first, finding a safe dose, then testing that dose in more people to see how well it works and how …
Phase 1 • Sponsor: Immunome, Inc. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Which drug first? trial tests sequence of carboplatin and olaparib in aggressive prostate cancer
Disease control Recruiting nowResearchers are comparing two sequences of treatment for metastatic castration-resistant prostate cancer that carries certain DNA repair gene mutations. Participants receive either carboplatin first and olaparib second, or olaparib first and carboplatin second, switching after th…
Phase 2 • Sponsor: VA Office of Research and Development • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New hope for endometrial cancer: targeted drug BNT323 faces chemo in phase 3 trial
Disease control Recruiting nowThis Phase 3 trial tests whether the drug BNT323 (trastuzumab pamirtecan) works better than standard chemotherapy for people with recurrent endometrial cancer that expresses HER2. About 480 participants will be split into two groups based on their HER2 levels. The study measures …
Phase 3 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Could a new drug combo beat standard chemo for kids with AML?
Disease control Recruiting nowThis large phase 3 trial is testing whether a new formulation of two chemotherapy drugs (CPX-351) and a targeted drug called gilteritinib can improve outcomes for children and young adults with newly diagnosed acute myeloid leukemia (AML). The study compares these new approaches …
Phase 3 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
First-in-Human trial asks whether HG381 is safe and tolerable in advanced solid tumors
Disease control Recruiting nowResearchers are running a first-in-human Phase 1 trial of HG381, an experimental drug given by intravenous injection, in adults with advanced solid tumors that have worsened after available treatments. The study aims to find out how safe and tolerable the drug is, how the body pr…
Phase 1 • Sponsor: HitGen Inc. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New immunotherapy duo aims to outdo chemo for common lymphoma
Disease control Recruiting nowThis large phase 2/3 trial is testing whether a new immunotherapy drug called MK-1045, when combined with the targeted therapy rituximab, can treat follicular lymphoma better than the current standard of rituximab plus chemotherapy. About 960 people with previously untreated foll…
Phase 2/3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Personalized chemo boosts CAR T-Cell success in young leukemia patients
Disease control Recruiting nowThis study tests whether giving a personalized dose of the chemotherapy drug fludarabine before CAR T-cell therapy can improve outcomes for children and young adults with relapsed or hard-to-treat B-cell acute lymphoblastic leukemia. About 130 participants will be randomly assign…
Phase 3 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New hope for lymphoma patients: targeted drug combo aims to delay cancer return
Disease control Recruiting nowThis study tests whether adding the targeted drug zilovertamab vedotin to standard chemotherapy (R-CHP) helps people with untreated diffuse large B-cell lymphoma live longer without their cancer growing or spreading, compared to the current standard treatment (R-CHOP). About 1,04…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New cancer drug GI-108 enters human trials for advanced tumors
Disease control Recruiting nowThis study tests a new drug called GI-108 in people with advanced or metastatic solid tumors, including lung, head and neck, pancreatic, and kidney cancers. The drug is designed to boost the immune system's ability to fight cancer. The trial will first find the safest dose, then …
Phase 1/2 • Sponsor: GI Innovation, Inc. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Prostate cancer radiation in one day? new study tests faster treatment
Disease control Recruiting nowThis study tests a new way to deliver radiation therapy for early-stage prostate cancer. Instead of two separate sessions days apart, both radiation doses are given just three hours apart on the same day. The goal is to see if this is safe and could make treatment more convenient…
Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New hope for tough prostate cancer: phase 3 trial launches
Disease control Recruiting nowThis study tests a new drug called opevesostat (plus hormone replacement therapy) against two standard treatments (abiraterone or enzalutamide) in about 1,300 men with metastatic castration-resistant prostate cancer that got worse after one prior hormone therapy. The goal is to s…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Exercise after cancer therapy: a new way to gauge prognosis?
Disease control Recruiting nowThis trial tests whether a high-intensity interval training (HIIT) program can help head and neck cancer patients maintain or improve muscle mass after chemoradiotherapy. Researchers will use imaging and blood tests to see if changes in muscle and inflammation markers can predict…
Sponsor: Chang Gung Memorial Hospital • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Two drugs aim to restore energy factories in rare muscle disease
Disease control Recruiting nowResearchers are testing a combination of two drugs, doxecitine and doxribtimine, in adults with thymidine kinase 2 (TK2) deficiency, a rare genetic condition that causes muscle weakness and breathing problems. The study will enroll about 15 adults with moderate to severe disease.…
Phase 2 • Sponsor: Cristina Domínguez González • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New pill could slow blindness in inherited eye disease
Disease control Recruiting nowThis early-stage trial tests a new oral drug called OCT-980 for people with a specific inherited eye disease (autosomal dominant retinitis pigmentosa) that causes gradual vision loss and blindness. The study first gives a single dose to healthy volunteers to check safety, then mu…
Phase 1/2 • Sponsor: Octant, Inc. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Can a vegan diet delivered online help people with type 2 diabetes?
Disease control Recruiting nowResearchers are testing a 12-week online program that teaches adults with type 2 diabetes and excess weight to follow a low-fat vegan diet. Participants meet weekly with a physician and a registered dietitian for education and support. The team measures body composition, blood su…
Sponsor: Physicians Committee for Responsible Medicine • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Gut bacteria may boost lung cancer therapy
Disease control Recruiting nowThis study tests whether taking special gut bacteria capsules (RMT) alongside standard chemotherapy and immunotherapy can help control advanced lung cancer. About 82 people with untreated non-small cell lung cancer will receive either RMT or a placebo. The goal is to see if the b…
Phase 2 • Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New pill combo aims to tame advanced prostate cancer
Disease control Recruiting nowThis study tests a new drug called HRS-5041, taken as a pill, combined with other cancer treatments for men with advanced prostate cancer. The goal is to see if the combination is safe and helps control the cancer. About 100 men aged 18 to 80 will take part. The study is currentl…
Phase 1/2 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New combo therapy takes on advanced cancers
Disease control Recruiting nowThis early-stage study tests a new drug called N-3C01, given alone or with an immunotherapy, in people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safety, find the right dose, and see if the combination shrinks tumors. About 114 a…
Phase 1/2 • Sponsor: Hefei Xinzhu Biological Technology Co., Ltd. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New hope for lung scarring? drug trial aims to slow breathing decline
Disease control Recruiting nowThis study tests two doses of an experimental drug, zampilimab, against a placebo in 240 adults with idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs and makes breathing hard. The main goal is to see if the drug can improve lung function over 24 weeks, with an …
Phase 2 • Sponsor: Chiesi Farmaceutici S.p.A. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
AI-Designed drug targets scarred lungs in major trial
Disease control Recruiting nowThis phase 3 trial tests whether the oral drug rentosertib (INS018_055) can slow lung function decline in adults with idiopathic pulmonary fibrosis (IPF), a progressive lung disease. About 320 participants will receive either rentosertib or a placebo daily for 52 weeks. The main …
Phase 3 • Sponsor: InSilico Medicine Hong Kong Limited • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New lupus pill enters Mid-Stage trial – hope for better control?
Disease control Recruiting nowThis study tests an experimental oral drug called BI 3000202 in 405 adults with moderate to severe systemic lupus erythematosus (SLE). Participants are randomly assigned to one of four doses of the drug or a placebo, taken daily for a year alongside their usual lupus treatments. …
Phase 2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New drug aims to control advanced cervical cancer
Disease control Recruiting nowThis phase 2 trial tests a drug called lorigerlimab (MGD019) in 47 people with advanced cervical cancer that has spread or come back. The goal is to see if the drug can help control the cancer and improve survival. Participants receive the drug through an IV. The study is current…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New drug aims to outperform chemo in tough bladder cancer
Disease control Recruiting nowThis phase 3 trial tests whether the experimental drug sacituzumab tirumotecan helps people with advanced bladder cancer live longer than standard chemotherapy. About 590 participants whose cancer worsened after prior treatments will receive either the new drug or one of several …
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Broccoli vs. bladder cancer: could your diet keep tumors away?
Disease control Recruiting nowThis study tests a healthy eating program that encourages people with early-stage bladder cancer to eat more cruciferous vegetables like broccoli, kale, and cabbage. These veggies contain natural compounds that may help fight cancer cells. Researchers want to see if this diet cha…
Phase 2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New eye drug aims to offer cheaper option for blinding disease
Disease control Recruiting nowThis phase 3 trial tests whether a new drug called ABP 938 works as well as the approved treatment Eylea HD for wet age-related macular degeneration, a leading cause of vision loss. About 304 people aged 50 and older with untreated wet AMD will receive injections of either drug i…
Phase 3 • Sponsor: Amgen • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New pill aims to slow kidney disease in IgA nephropathy patients
Disease control Recruiting nowThis study tests an experimental drug called STL303 for people with IgA nephropathy, a kidney disease. About 15 adults will receive either STL303 or a placebo to see if the drug is safe and can reduce protein in the urine, a sign of kidney damage. Possible side effects include na…
Phase 2 • Sponsor: Sitala Bio LTD • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New hope for Hard-to-Treat breast cancer: BNT327 combo enters phase 3 trial
Disease control Recruiting nowThis phase 3 trial tests whether adding the experimental drug BNT327 to standard chemotherapy helps people with advanced triple-negative breast cancer (TNBC) live longer without their cancer growing. Participants have TNBC that cannot be treated with current PD(L)1 immunotherapie…
Phase 3 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New PET tracer could spot hidden fungal infections
Diagnosis Recruiting nowThis Phase 1 trial tests a new radioactive tracer called [18F]-Fluorocellobiose ([18F]FCB) for PET/CT scans. The goal is to see if it can help find invasive mold infections in the body. The study includes healthy volunteers and people with known fungal infections. Participants re…
Phase 1 • Sponsor: National Institutes of Health Clinical Center (CC) • Aim: Diagnosis
Last updated Sep 20, 2026 00:00 UTC
-
Tiny magnetic seeds could guide surgeons to the right lymph node
Diagnosis Recruiting nowResearchers are testing whether a small implantable marker called Magseed, along with a handheld magnetic probe called Sentimag, can help surgeons locate and remove a specific axillary lymph node in breast cancer patients who have had chemotherapy before surgery. The study enroll…
Sponsor: Endomagnetics Ltd. • Aim: Diagnosis
Last updated Sep 20, 2026 00:00 UTC
-
Can AI learn to spot endometriosis and fibroids on ultrasound?
Diagnosis Recruiting nowResearchers at Semmelweis University are building and testing artificial intelligence algorithms that read standardized transvaginal ultrasound images. The study includes women aged 18 to 45 who have suspected endometriosis or adenomyosis, a confirmed uterine mass scheduled for s…
Sponsor: Semmelweis University • Aim: Diagnosis
Last updated Sep 20, 2026 00:00 UTC
-
Blowing away breast cancer: a breath test could spot the disease early
Diagnosis Recruiting nowThis study is testing whether a breath test can detect breast cancer in women aged 40 to 74. Researchers will collect breath samples from over 5,000 women before their standard biopsy or MRI and compare the chemical patterns between those found to have cancer and those who do not…
Sponsor: Breathe BioMedical Inc • Aim: Diagnosis
Last updated Sep 20, 2026 00:00 UTC
-
Can a Brain-Tumor dye light up kidney cancer during surgery?
Diagnosis Recruiting nowResearchers are testing whether a drug called 5-aminolevulinic acid (5-ALA) can make kidney tumors glow under blue light during surgery. Adults with suspected kidney cancer take the drug by mouth before a partial nephrectomy, a procedure that removes part of the kidney. Surgeons …
Phase 2 • Sponsor: Henry Ford Health System • Aim: Diagnosis
Last updated Sep 20, 2026 00:00 UTC
-
Radioactive tracer lights up Oxygen-Starved brain tumors
Diagnosis Recruiting nowResearchers are testing a radioactive tracer called FMISO with PET/MRI scans to map oxygen levels inside malignant brain tumors. Adults with a suspected glioma receive the tracer by IV, then undergo brain scans that combine PET and MRI, sometimes with contrast dyes. The study che…
Phase 2 • Sponsor: OHSU Knight Cancer Institute • Aim: Diagnosis
Last updated Sep 20, 2026 00:00 UTC
-
Pen-Like device could help surgeons detect cancer in real time
Diagnosis Recruiting nowThis study tests whether a handheld device called the MasSpec Pen can tell the difference between cancerous MPNST, benign neurofibromas, and normal tissue during surgery. About 60 people with MPNST or neurofibroma will take part. The goal is to see if the device is safe and accur…
Sponsor: M.D. Anderson Cancer Center • Aim: Diagnosis
Last updated Sep 20, 2026 00:00 UTC
-
Glow-in-the-dark dye could help surgeons find hidden cancers
Diagnosis Recruiting nowThis study tests whether a medication called 5-ALA, already used in brain surgery, can make upper urinary tract tumors glow under blue light during surgery. About 10 adults with known or suspected tumors will take 5-ALA before their procedure. The goal is to see if this technique…
Phase 2 • Sponsor: Henry Ford Health System • Aim: Diagnosis
Last updated Sep 20, 2026 00:00 UTC
-
New PET tracer aims to light up HER2 breast cancer
Diagnosis Recruiting nowResearchers are testing a new PET imaging tracer called 18F-HER2 Affibody to see how well it detects HER2-expressing breast cancer. The study includes 40 adults with confirmed or suspected HER2-positive breast cancer. Participants receive the tracer and then undergo a PET scan. T…
Sponsor: The Affiliated Hospital of Qingdao University • Aim: Diagnosis
Last updated Sep 19, 2026 00:00 UTC
-
New imaging agent could reveal prostate cancer treatment success in real time
Diagnosis Recruiting nowThis phase 2 trial is testing whether a special PET scan tracer called 18F-DCFPyL can accurately show how prostate cancer responds to standard radiation therapy. About 130 adults with newly diagnosed, localized prostate cancer will receive the tracer and undergo PET/CT scans at s…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Diagnosis
Last updated Sep 19, 2026 00:00 UTC
-
Green dye vs blue dye: which finds Cancer-Linked lymph nodes better?
Diagnosis Recruiting nowResearchers compare two tracers, indocyanine green (ICG) and blue patent dye, for locating lymph nodes during targeted axillary dissection in breast cancer patients who have received chemotherapy before surgery. The trial measures how often each tracer successfully identifies the…
Sponsor: Hospital Universitari de Bellvitge • Aim: Diagnosis
Last updated Sep 19, 2026 00:00 UTC
-
New 3D ultrasound aims to improve breast cancer diagnosis without radiation
Diagnosis Recruiting nowThis study is testing a new 3D automated ultrasound system called ATUSA to see how well it can image suspicious breast lesions. Up to 800 women with suspicious findings on standard imaging will get an ATUSA scan before their biopsy. The goal is to collect images and compare them …
Sponsor: iSono Health, Inc. • Aim: Diagnosis
Last updated Sep 19, 2026 00:00 UTC
-
New AI-Powered swab test aims to spot viruses in minutes
Diagnosis Recruiting nowThis study tests a new technology called Pictura Bio that aims to detect respiratory viruses quickly and cheaply from nose or throat swabs. Researchers will collect samples from 1000 adults and children with suspected viral infections at a UK hospital. The data will be used to tr…
Sponsor: Portsmouth Hospitals NHS Trust • Aim: Diagnosis
Last updated Sep 19, 2026 00:00 UTC
-
One-Hour test could revolutionize pneumonia treatment in hospitals
Diagnosis Recruiting nowThis study compares a rapid test that identifies pneumonia-causing bacteria in about one hour to standard lab methods that take 2-4 days. Researchers want to see if the faster test helps doctors choose the right antibiotics sooner for 150 hospitalized patients with pneumonia. The…
Sponsor: Hospital de Clinicas de Porto Alegre • Aim: Diagnosis
Last updated Sep 19, 2026 00:00 UTC
-
Light-Based imaging aims to spot prostate cancer left behind after surgery
Diagnosis Recruiting nowAfter surgery to remove prostate cancer, cancer cells sometimes remain at the edge of the removed tissue, which can lead to the cancer returning. Researchers are testing a light-based imaging method called hyperspectral imaging to examine the removed prostate and identify cancer …
Sponsor: Massimo Valerio • Aim: Diagnosis
Last updated Sep 19, 2026 00:00 UTC
-
Gut bacteria and genes eyed as keys to predicting repeat c. diff
Diagnosis Recruiting nowResearchers are studying adults with Clostridioides difficile infection to learn why some people get a repeat infection. The trial follows 750 patients across multiple hospitals, collecting blood for genetic testing and stool samples to examine gut bacteria. The goal is to build …
Sponsor: Hospital Universitario de Valme • Aim: Diagnosis
Last updated Sep 19, 2026 00:00 UTC
-
Radioactive tracer aims to spot kidney cancer with sharper eyes
Diagnosis Recruiting nowResearchers are testing a radioactive tracer called 18F-NY104 to see how well it detects kidney cancer and other tumors that carry a protein called CAIX. About 120 people with known or suspected kidney cancer, or other CAIX-positive cancers, will receive an injection of the trace…
Sponsor: The Affiliated Hospital of Qingdao University • Aim: Diagnosis
Last updated Sep 19, 2026 00:00 UTC
-
AI-Enhanced ultrasound aims to catch liver cancer earlier
Diagnosis Recruiting nowResearchers are testing whether advanced ultrasound techniques combined with machine learning can improve the detection and characterization of liver cancer compared to standard ultrasound. The study enrolls 200 adults who have a focal liver lesion visible on ultrasound or are in…
Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) • Aim: Diagnosis
Last updated Sep 19, 2026 00:00 UTC
-
New scan could spot hidden pancreatic cancer spread
Diagnosis Recruiting nowThis phase 3 trial is testing a new type of PET scan that uses a radioactive tracer called [18F]FAPI-74 to detect whether pancreatic cancer has spread to other parts of the body. About 200 adults with pancreatic cancer will receive one dose of the tracer and then be scanned. The …
Phase 3 • Sponsor: SOFIE • Aim: Diagnosis
Last updated Sep 19, 2026 00:00 UTC
-
Can a gentle eye scan replace stressful exams for preterm infants?
Diagnosis Recruiting nowThis study tests whether a handheld, ultra-widefield eye scanner (OCT) can accurately identify preterm infants with severe retinopathy of prematurity (ROP), a condition that can harm vision. The scanner takes detailed images of the retina without touching the eye, potentially red…
Sponsor: Duke University • Aim: Diagnosis
Last updated Sep 19, 2026 00:00 UTC
-
New scan aims to spot hidden cancer spread in stomach and esophageal tumors
Diagnosis Recruiting nowThis study is testing a new type of PET/CT scan called [¹⁸F]FAPI-74 to see if it can better detect when stomach or esophageal cancer has spread to other parts of the body. About 200 adults with these cancers will receive one dose of the scan tracer and be followed for up to 3 mon…
Phase 3 • Sponsor: SOFIE • Aim: Diagnosis
Last updated Sep 19, 2026 00:00 UTC
-
Can PET scans reveal which stomach cancers will respond to immunotherapy?
Diagnosis Recruiting nowResearchers at Ruijin Hospital are testing two PET imaging tracers, FAPI and Grazytracer, to see if they can predict how well advanced gastric cancer responds to preoperative immunotherapy. The study enrolls 120 adults with resectable or advanced gastric cancer. Participants rece…
Sponsor: Ruijin Hospital • Aim: Diagnosis
Last updated Sep 19, 2026 00:00 UTC
-
Personalized navigation may boost cancer screening in high-risk communities
Prevention Recruiting nowThis study tests whether giving people a personalized report about their cancer risk and screening options helps them complete recommended cancer tests. Adults aged 45 to 74 who are at high risk for lung, breast, colorectal, upper gastrointestinal, or liver cancer are invited to …
Sponsor: Hunan Cancer Hospital • Aim: Prevention
Last updated Sep 20, 2026 00:00 UTC
-
Could STI testing be the key to getting more women on HIV prevention?
Prevention Recruiting nowThis study in Uganda tests whether adding lab tests for common sexually transmitted infections (STIs) to standard HIV risk screening helps more women start and stick with PrEP, a daily pill that prevents HIV. About 4,500 HIV-negative women aged 15-39 will be randomly assigned to …
Sponsor: Johns Hopkins University • Aim: Prevention
Last updated Sep 20, 2026 00:00 UTC
-
New model aims to eliminate HIV transmission from mothers to infants in malawi
Prevention Recruiting nowThis study is testing a new approach called PAC-Man to help prevent HIV from passing from mothers to their babies. About 2,426 mothers and infants in Malawi will take part. The goal is to see if this model helps more babies get tested for HIV early and ensures mothers receive pro…
Sponsor: University of North Carolina, Chapel Hill • Aim: Prevention
Last updated Sep 20, 2026 00:00 UTC
-
Monthly HIV prevention pill could replace daily dose
Prevention Recruiting nowThis phase 3 trial tests MK-8527, a once-monthly oral pill, to prevent HIV-1 infection in women. About 4580 HIV-negative women will take either MK-8527 monthly or a daily PrEP pill (Truvada) to see which works better and is safer. The goal is to offer a more convenient prevention…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Prevention
Last updated Sep 20, 2026 00:00 UTC
-
Can immunotherapy given around liver cancer surgery stop the disease from coming back?
Prevention Recruiting nowResearchers are testing whether a combination immunotherapy called iparomlimab and tuvonralimab can prevent liver cancer from returning after surgery in patients whose tumors are at high risk of coming back. Participants receive one dose of the immunotherapy before surgery to rem…
Phase 2 • Sponsor: Tongji Hospital • Aim: Prevention
Last updated Sep 20, 2026 00:00 UTC
-
Thymus cells may teach a new heart to be left alone
Prevention Recruiting nowChildren who receive a heart transplant need powerful drugs to stop their immune system from attacking the new organ. Researchers are testing a different approach: they collect regulatory T cells, a type of immune cell that dampens rejection, from thymus tissue that is normally d…
Phase 1/2 • Sponsor: Rafael Correa-Rocha • Aim: Prevention
Last updated Sep 20, 2026 00:00 UTC
-
Burning the edges: a new way to stop colon polyps from coming back
Prevention Recruiting nowLarge colorectal polyps can turn into cancer, so doctors remove them during a colonoscopy. Even after removal, polyps often grow back. This trial compares two methods for sealing the area where the polyp was removed: one uses a water jet to lift tissue and then burns it with argo…
Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) • Aim: Prevention
Last updated Sep 20, 2026 00:00 UTC
-
Can a Three-Session couples program cut drug use and HIV risk?
Prevention Recruiting nowResearchers are testing whether a three-session couples motivational interviewing program helps male couples reduce illicit drug use and behaviors that raise HIV transmission risk. The trial enrolls 360 male couples where at least one partner is HIV negative and at least one has …
Sponsor: Hunter College of City University of New York • Aim: Prevention
Last updated Sep 19, 2026 00:00 UTC
-
Can AI-Tailored heat warnings shield chronic disease patients from dangerous temperatures?
Prevention Recruiting nowResearchers in Pakistan are testing whether a mobile app that uses artificial intelligence to send personalized heat-risk alerts can reduce heat-related illness symptoms in adults with chronic conditions such as hypertension, diabetes, kidney disease, heart disease, or obesity. T…
Sponsor: National University of Medical Sciences, Pakistan • Aim: Prevention
Last updated Sep 19, 2026 00:00 UTC
-
Could everyday supplements turn back the clock on aging?
Prevention Recruiting nowThis trial tests whether two natural supplements—quercetin (from foods like apples and onions) and coenzyme Q10 (a substance your body makes)—can reduce inflammation and improve metabolic health in older adults. Over 12 weeks, participants aged 50 to 75 who are sedentary will tak…
Sponsor: Applied Science & Performance Institute • Aim: Prevention
Last updated Sep 19, 2026 00:00 UTC
-
Can pharmacy training boost HPV shots and prevent future cancers?
Prevention Recruiting nowThis study looks at whether training pharmacy staff to better communicate about and manage the HPV vaccine can increase vaccination rates in children ages 9-17. About 1,900 participants, including pharmacy staff and parents, will be involved. The goal is to make it easier for fam…
Sponsor: Fred Hutchinson Cancer Center • Aim: Prevention
Last updated Sep 19, 2026 00:00 UTC
-
Can treating anemia before pregnancy stop it later?
Prevention Recruiting nowResearchers compare two strategies for finding and treating iron deficiency anemia in women who plan to become pregnant. One group gets screening and iron supplements before conception, while the other gets screening and treatment at 12 weeks of pregnancy. The trial measures how …
Sponsor: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Prevention
Last updated Sep 19, 2026 00:00 UTC
-
Brain pacemaker tweak could help stroke and tremor patients speak and swallow better
Symptom relief Recruiting nowThis study looks at whether adjusting deep brain stimulation (DBS) can improve movement, speech, and swallowing in people already implanted with DBS for conditions like tremor, stroke, or traumatic brain injury. Researchers will test hand dexterity, grip strength, facial movement…
Sponsor: Jorge Gonzalez-Martinez • Aim: Symptom relief
Last updated Sep 20, 2026 00:00 UTC
-
A lens that could let cataract patients see near and far without glasses
Symptom relief Recruiting nowCataracts cloud the eye's lens and blur vision, and presbyopia makes it hard to focus up close after age 50. Researchers are testing an intraocular lens with a virtual aperture optic, implanted during cataract surgery, to see if it improves vision at distance, intermediate, and n…
Sponsor: Z Optics, Inc. • Aim: Symptom relief
Last updated Sep 20, 2026 00:00 UTC
-
Can nature sounds ease grief? new study tests meditation for cancer caregivers
Symptom relief Recruiting nowThis study tests whether a nature-based healing meditation program can help friends and family caregivers who are grieving the loss of a loved one to cancer. The program includes six audio meditation modules available online. Researchers will measure how feasible and acceptable t…
Sponsor: Michigan State University • Aim: Symptom relief
Last updated Sep 20, 2026 00:00 UTC
-
FLASH therapy: a flash of hope for head and neck cancer retreatment?
Symptom relief Recruiting nowThis early study tests a new type of radiation therapy called ConformalFLASH, which delivers radiation at an ultra-high speed. It is for 10 adults with head and neck cancer who need a second round of radiation but cannot have surgery. The goal is to see if this fast treatment is …
Sponsor: IBA Proton Therapy, Inc. • Aim: Symptom relief
Last updated Sep 20, 2026 00:00 UTC
-
Exercise with or without compression: a new hope for leg swelling?
Symptom relief Recruiting nowThis study looks at whether doing resistance exercises (like leg presses) can reduce swelling in the lower legs of people with lymphedema. It also checks if wearing compression garments during exercise makes a difference. Thirty-six adults with lower limb lymphedema will exercise…
Sponsor: Carsten Bogh Juhl • Aim: Symptom relief
Last updated Sep 20, 2026 00:00 UTC
-
Taurine trial targets long COVID brain fog
Symptom relief Recruiting nowThis study tests whether taking taurine supplements can reduce brain fog, memory problems, and fatigue in people with Long COVID. About 300 adults who had COVID-19 at least 3 months ago will take taurine or a placebo for 3 months. Researchers will measure changes in fatigue and t…
Phase 2/3 • Sponsor: University of Alberta • Aim: Symptom relief
Last updated Sep 20, 2026 00:00 UTC
-
Can a cancer drug calm the nosebleeds of a rare bleeding disorder?
Symptom relief Recruiting nowHereditary hemorrhagic telangiectasia (HHT) causes tangled blood vessels that lead to frequent, hard-to-stop nosebleeds and low hemoglobin. Researchers are testing whether intravenous bevacizumab, given once or twice a year after nasal electrocoagulation, reduces nosebleed severi…
Phase 2 • Sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine • Aim: Symptom relief
Last updated Sep 20, 2026 00:00 UTC
-
Can a Weight-Loss drug ease rett syndrome?
Symptom relief Recruiting nowThis Phase 3 trial tests whether fenfluramine (Fintepla) can reduce behavioral and emotional symptoms in people with Rett syndrome. About 200 participants will receive either the drug or a placebo for 14 weeks. The study measures changes in behavior, sleep, and overall condition …
Phase 3 • Sponsor: UCB BIOSCIENCES, Inc. • Aim: Symptom relief
Last updated Sep 20, 2026 00:00 UTC
-
Pre-Radiation pelvic therapy may ease pain and sexual issues for women with pelvic cancers
Symptom relief Recruiting nowThis study looks at whether adding pelvic floor physical therapy before standard radiation treatment can help reduce pain and sexual problems in women with cervical, vaginal, vulvar, uterine, or anal cancer. About 20 participants will receive education on using a vaginal dilator …
Sponsor: Indiana University • Aim: Symptom relief
Last updated Sep 20, 2026 00:00 UTC
-
New therapy aims to help kids with speech disorder speak in phrases
Symptom relief Recruiting nowThis study tests a speech therapy called DTTC-Connect for children aged 3 to 12 with childhood apraxia of speech, a disorder that makes it hard to say words clearly. The therapy focuses on helping children move from saying single words to speaking in phrases. Sixty-eight children…
Sponsor: New York University • Aim: Symptom relief
Last updated Sep 20, 2026 00:00 UTC
-
Can AI tailor recovery instructions after lung cancer surgery?
Symptom relief Recruiting nowResearchers are testing whether an AI-generated, personalized discharge plan improves the quality of discharge teaching and recovery for people who had lung cancer surgery. The trial enrolls 156 adults who had surgery for stage I to III lung cancer and are going home to recover. …
Sponsor: Xiamen University • Aim: Symptom relief
Last updated Sep 20, 2026 00:00 UTC
-
Can video games calm anxious teens?
Symptom relief Recruiting nowResearchers are testing whether playing video games can reduce anxiety in adolescents aged 11 to 15 with elevated anxiety symptoms. The trial compares an action game designed to boost attention control, a casual puzzle game, and no game at all. Teens play at home online for six w…
Sponsor: School of Health Sciences Geneva • Aim: Symptom relief
Last updated Sep 20, 2026 00:00 UTC
-
Tiny One-Way valves for emphysema under close watch in japan
Symptom relief Recruiting nowResearchers in Japan are observing 140 people with severe emphysema who receive Zephyr Endobronchial Valves, tiny one-way valves placed in the lungs to reduce hyperinflation. The surveillance follows participants for 12 months across up to 20 centers. The main goal is to measure …
Sponsor: Pulmonx Corporation • Aim: Symptom relief
Last updated Sep 19, 2026 00:00 UTC
-
Light therapy app aims to ease dry mouth for cancer survivors
Symptom relief Recruiting nowThis study tests whether a special light therapy (photobiomodulation) combined with a mobile health app can improve dry mouth and quality of life in people who have had head and neck cancer and completed radiation. Sixty participants will receive either real light therapy or a sh…
Sponsor: Universidad de Granada • Aim: Symptom relief
Last updated Sep 19, 2026 00:00 UTC
-
Could a common anxiety drug help autistic youth? new trial aims to find out.
Symptom relief Recruiting nowThis study tests whether buspirone, a medication used for anxiety, is safe and effective for autistic youth aged 7 to 17 who also have anxiety disorders. Researchers will measure changes in anxiety symptoms over 16 weeks. The goal is to see if this drug can ease anxiety in this s…
Phase 4 • Sponsor: Massachusetts General Hospital • Aim: Symptom relief
Last updated Sep 19, 2026 00:00 UTC
-
New study could spare breast cancer patients from underarm surgery
Symptom relief Recruiting nowThis study compares two approaches for breast cancer patients who still have cancer in their sentinel lymph node after chemotherapy: removing the underarm lymph nodes (surgery) or treating them with radiation. The goal is to see if radiation can reduce the risk of arm swelling (l…
Sponsor: Hospital Universitari de Bellvitge • Aim: Symptom relief
Last updated Sep 19, 2026 00:00 UTC
-
Can an art app help young cancer survivors feel better?
Symptom relief Recruiting nowThis study tests whether a digital art therapy app called ARTCan is practical and acceptable for young adults aged 18-25 who survived childhood cancer. Participants use the app for 6 weeks to create art and complete mood surveys. The goal is to see if at least 10 out of 15 partic…
Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Symptom relief
Last updated Sep 19, 2026 00:00 UTC
-
Three shots, one wrist: which injection best eases carpal tunnel?
Symptom relief Recruiting nowCarpal tunnel syndrome happens when the median nerve gets squeezed at the wrist, causing numbness, tingling, and pain in the hand. This study compares three ultrasound-guided injections for adults with mild to moderate cases: hyaluronic acid, corticosteroid, and 5% glucose. Sixty…
Early phase 1 • Sponsor: Tanta University • Aim: Symptom relief
Last updated Sep 19, 2026 00:00 UTC
-
Can an old blood vessel drug shorten labour when waters break at term?
Symptom relief Recruiting nowWhen a woman's waters break at term but labour has not started, doctors often use oxytocin to get contractions going. This trial tests whether adding a single intravenous dose of papaverine, a drug that relaxes smooth muscle, helps oxytocin work faster. Two hundred women with ter…
Sponsor: Wolfson Medical Center • Aim: Symptom relief
Last updated Sep 19, 2026 00:00 UTC
-
Can a group program teach teens to cope before therapy starts?
Symptom relief Recruiting nowResearchers at Penn State are testing whether the BaSICS program reduces anxiety, depression, and suicide risk in 11- to 14-year-olds from low-income families who are waiting for mental health services. The program teaches coping skills, healthy identity development, and collecti…
Sponsor: Penn State University • Aim: Symptom relief
Last updated Sep 19, 2026 00:00 UTC
-
Coloring books in the ER: a simple fix for long waits?
Symptom relief Recruiting nowThis study tests whether giving coloring activities (nature scenes, geometric shapes, word searches, or free drawing) to adults waiting in the emergency department can lower their self-reported pain and anxiety. Researchers will measure changes using standard questionnaires. If e…
Sponsor: Stony Brook University • Aim: Symptom relief
Last updated Sep 19, 2026 00:00 UTC
-
New pain relief hope for lung cancer patients: nerve block via port
Symptom relief Recruiting nowThis study tests whether a nerve block given through a small port under the skin can help control chest pain in people with advanced lung cancer. The block delivers numbing medicine near the chest wall nerves. Researchers will compare pain levels and side effects in 180 patients …
Sponsor: Hanoi Medical University • Aim: Symptom relief
Last updated Sep 19, 2026 00:00 UTC
-
New surgery aims to eater eating for stomach cancer patients
Symptom relief Recruiting nowThis trial compares a new surgery called partial stomach-partitioning gastrojejunostomy (SPGJ) to the standard surgery for relieving stomach blockage in advanced gastric cancer. The goal is to see which surgery better helps patients eat normally, with fewer complications like del…
Sponsor: Guangxi Medical University • Aim: Symptom relief
Last updated Sep 19, 2026 00:00 UTC
-
Laser zaps prostate troubles without cutting
Symptom relief Recruiting nowThis study compares a new laser procedure (TPLA) to standard surgery (TURP) for men with urinary symptoms caused by an enlarged prostate. Researchers want to see if the laser works just as well, with possibly fewer side effects. About 80 men will take part.
Sponsor: Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari • Aim: Symptom relief
Last updated Sep 19, 2026 00:00 UTC
-
Can a massive data registry crack the code of Parkinson's and related brain diseases?
Knowledge-focused Recruiting nowResearchers are building a large database of cognitive, behavioral, lifestyle, and genetic information from people with neurodegenerative diseases such as Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. The goal is to find biomarkers that help do…
Sponsor: Vincent Mok • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
NIH launches massive hunt to solve medical mysteries for thousands
Knowledge-focused Recruiting nowThis study aims to diagnose people with severe, undiagnosed conditions that have baffled doctors. Up to 20,000 participants will undergo advanced genetic testing and clinical exams at multiple research centers. The goal is to provide answers, discover new diseases, and improve ca…
Sponsor: National Human Genome Research Institute (NHGRI) • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Could a dye reveal hidden scarring in Crohn's patients?
Knowledge-focused Recruiting nowThis study tests a new imaging method using a special dye (FAPI) to detect bowel scarring in people with Crohn's disease. Scarring affects up to half of patients and often leads to surgery, but current tests can't spot it early. The study will involve 30 adults starting biologic …
Sponsor: University of Edinburgh • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Scientists launch national study to track immune weakness linked to severe COVID
Knowledge-focused Recruiting nowThis study follows 500 adults in France who have either a genetic defect or autoantibodies that weaken their type I interferon immune response. Researchers will collect blood samples and health data over 1 to 4 years to track infections, autoimmune diseases, and cancers. The goal…
Sponsor: Institut National de la Santé Et de la Recherche Médicale, France • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Tonsils shed light on staph Bacteria's secrets
Knowledge-focused Recruiting nowThis study aims to understand how Staphylococcus aureus bacteria interact with human cells to cause infections, especially in the spine. Researchers will use tonsil tissue discarded after routine tonsillectomies to create lab models. About 500 participants aged 2 and older who ar…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Reading the Brain's signals to predict who benefits from deep brain stimulation
Knowledge-focused Recruiting nowDeep brain stimulation uses implanted electrodes to send electrical pulses to specific brain regions, and doctors are still working out how to tune it for each patient. This study records brain activity while adults with neurological or psychiatric conditions perform cognitive an…
Sponsor: Centre Hospitalier St Anne • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Queensland study reveals why parents say yes or no to RSV shot for babies
Knowledge-focused Recruiting nowThis study observes how many eligible infants in Queensland receive the RSV immunisation (nirsevimab) during their first RSV season. Researchers will survey 1,200 parents to understand why they chose for or against the shot, and look at factors like location and health risks. No …
Sponsor: Sanofi • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Ovarian Cancer's spread: scientists probe abdominal fluid for clues
Knowledge-focused Recruiting nowResearchers at the University of New Mexico collect ascites fluid, the liquid that builds up in the abdomen, from women undergoing surgery for ovarian cancer. They study this fluid and tumor tissue in the lab to learn how the tumor environment helps cancer spread within the perit…
Sponsor: New Mexico Cancer Research Alliance • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Can what you eat help sickle cell? new study investigates diet and symptoms
Knowledge-focused Recruiting nowThis study looks at how diet and eating habits affect the health of adults with sickle cell disease. Researchers will interview participants about their food intake and behaviors, and collect blood and urine samples. The goal is to understand links between nutrition and symptoms …
Sponsor: National Institutes of Health Clinical Center (CC) • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Scientists expose volunteers to tick bites to unlock vaccine secrets
Knowledge-focused Recruiting nowThis study looks at how healthy people's skin and immune system respond to tick bites. Researchers will place clean, lab-bred ticks on volunteers' skin and take small skin samples and blood to track changes. The goal is to understand tick resistance and help design future vaccine…
Phase 1/2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Spinal fluid may hold clues to breast cancer brain spread
Knowledge-focused Recruiting nowThis study collects spinal fluid, blood, saliva, and tumor samples from 139 adults with HER2-positive or triple-negative breast cancer that has spread to other organs but not yet to the brain. Researchers will analyze these samples for tumor DNA that might predict when the cancer…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Scientists decode hidden links in deadly tropical infection
Knowledge-focused Recruiting nowThis study aims to understand how the environment, the bacteria that cause melioidosis, and the human body interact to cause disease. Researchers will follow about 1,000 infected patients and 1,000 healthy matched controls in Thailand, Laos, and Cambodia for one year. They will a…
Sponsor: University of Oxford • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Massive study aims to unlock secrets of movement disorders
Knowledge-focused Recruiting nowThis natural history study is collecting information from up to 4,000 people with movement disorders (like Parkinson's disease or tremor) and their family members. Participants undergo exams, blood tests, and imaging, but receive no new treatments. The goal is to gather data that…
Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
New study checks cancer Drug's effect on common medications
Knowledge-focused Recruiting nowThis study looks at how a cancer drug called pelabresib changes the way the body processes three other medicines: repaglinide (for diabetes), midazolam (a sedative), and a birth control pill. It involves 24 adults with advanced cancers who have no standard treatment options. The …
Phase 1 • Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Gene therapy survivors monitored for years in massive safety study
Knowledge-focused Recruiting nowThis study follows over 1,500 children and adults who previously received gene-modified T cell therapy for cancer. Researchers will track side effects, how long the modified cells last, and overall survival for up to 15 years. No new treatment is given—the goal is to understand l…
Phase 2/3 • Sponsor: Celgene • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Smart testing after CAR t: could it spare kids from unneeded transplants?
Knowledge-focused Recruiting nowThis study tests whether regular blood and bone marrow tests using advanced DNA sequencing can better monitor children with B-cell acute lymphoblastic leukemia (B-ALL) after they achieve remission with CAR T therapy. The goal is to see if these tests can identify who is truly cur…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Lyme disease mystery: do bacteria lurk after antibiotics?
Knowledge-focused Recruiting nowThis study investigates whether the bacteria causing Lyme disease can survive antibiotic treatment and cause ongoing symptoms. Researchers will follow 700 participants, including those with chronic Lyme disease, recovered individuals, and healthy volunteers, using blood tests, sp…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
New national registry aims to unlock secrets of Ultra-Rare childhood cancers
Knowledge-focused Recruiting nowThis study creates a registry for children, teens, and young adults (ages 1 month to 39 years) diagnosed with very rare solid tumors (fewer than 2 cases per million people per year). Researchers will collect medical records, tumor samples, and patient questionnaires to better und…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
New brain scans aim to spot inflammation in Alzheimer's and Parkinson's
Knowledge-focused Recruiting nowThis study uses special PET scans to measure inflammation in the brains of people with Alzheimer's, Parkinson's, ALS, and other neurodegenerative diseases. Researchers will compare these scans to those from healthy volunteers to see if inflammation levels differ. The goal is to d…
Phase 1 • Sponsor: National Institute of Mental Health (NIMH) • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Biomarker-Guided breast cancer trial aims to personalize therapy
Knowledge-focused Recruiting nowThis study is for people with metastatic breast cancer, including estrogen receptor-positive and triple-negative types. It uses biomarkers from tumors and blood to guide treatment choices, comparing how long the cancer stays controlled on the new therapy versus the previous one. …
Phase 2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Brain scans reveal hidden thinking problems in anemia patients
Knowledge-focused Recruiting nowThis study uses a non-invasive brain imaging technique called fNIRS to see how anemia affects thinking and memory. Researchers will measure brain activity in 323 adults with different types of anemia and compare it to cognitive test scores. The goal is to identify which brain reg…
Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Massive study aims to unlock genetic secrets of movement disorders
Knowledge-focused Recruiting nowThis study aims to understand the link between genes and symptoms in people with inherited movement disorders. Researchers will study up to 2,500 participants, including patients and their family members, to identify new disease-causing genes and improve diagnosis. The goal is to…
Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Can a Vitamin-Like pill boost fat burning on a keto diet?
Knowledge-focused Recruiting nowThis study looks at how a supplement called nicotinamide riboside (NR) and a low-carb, high-fat 'ketogenic' diet affect the way the body burns fat and uses energy. Researchers will measure changes in metabolism in 100 overweight or obese adults. Participants will eat a standard d…
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Heartburn drug under the microscope: registry tracks thousands of pregnancies
Knowledge-focused Recruiting nowResearchers are running an observational registry to study whether vonoprazan, an oral drug for heartburn and acid reflux, is safe to take during pregnancy. The study follows women aged 15 to 50 who took vonoprazan while pregnant and compares their outcomes with women who did not…
Sponsor: Phathom Pharmaceuticals, Inc. • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
New study tracks thyroid cancer patients outside clinical trials
Knowledge-focused Recruiting nowThis study observes adults with advanced thyroid cancer who are receiving standard treatments in real-world settings, not in clinical trials. Researchers aim to understand barriers to accessing care and how well patients tolerate and respond to available medications. About 459 pa…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Gene hunt in peru: could ancestry hold key to autoimmune diseases?
Knowledge-focused Recruiting nowThis study aims to uncover genetic changes that cause autoimmune diseases in people native to Peru. Researchers will collect blood, urine, and stool samples from 300 participants, including patients with conditions like lupus and rheumatoid arthritis, their family members, and he…
Sponsor: National Human Genome Research Institute (NHGRI) • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
New study uses genetic sequencing to solve mysterious childhood diseases
Knowledge-focused Recruiting nowThis study aims to find genetic causes of rare diseases in children aged 2 to 18 who live outside the United States and have limited access to genetic testing. Researchers will collect blood, saliva, or cheek swab samples from affected children and their family members. The goal …
Sponsor: National Human Genome Research Institute (NHGRI) • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Healthy volunteers willingly catch the flu for science
Knowledge-focused Recruiting nowThis study aims to find the safest and most effective dose of a specific flu virus to give to healthy adults in a controlled setting. About 90 volunteers aged 18 to 55 will be exposed to the virus or a placebo and closely monitored. The goal is to create a reliable model for test…
Phase 1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Can a simple questionnaire reveal why some cystic fibrosis patients skip physiotherapy?
Knowledge-focused Recruiting nowResearchers are translating the AdT-Physio scale into French and testing it in 121 adults with cystic fibrosis. The scale asks 15 questions about how often patients do their physiotherapy and what they believe about the treatment and their therapist. Participants also fill out qu…
Sponsor: Pole Sante Grace de Dieu • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Can imaging reveal how radiation shapes marrow recovery?
Knowledge-focused Recruiting nowThis study builds a registry of people who are receiving or have received radiation therapy for blood-related conditions. Researchers will gather medical records, imaging scans, lab results, and treatment data to see how radiation affects bone marrow reserve and patient outcomes.…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
New study checks how liver issues affect cancer drug pelabresib
Knowledge-focused Recruiting nowThis early-phase study is testing the cancer drug pelabresib in 24 people with advanced cancers who also have liver problems. The goal is to see how the liver affects the drug levels in the body. Participants will take the drug daily for 14 days, then have a week off. This resear…
Phase 1 • Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Simple skin test may spot Parkinson's risk years early
Knowledge-focused Recruiting nowThis study is testing whether a skin biopsy can detect abnormal proteins linked to Parkinson's disease in people with essential tremor, a common movement disorder. Researchers will follow 300 participants aged 50-85 for two years to see who develops Parkinson's. The goal is to fi…
Sponsor: CND Life Sciences • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Scientists zap brain during surgery to uncover movement secrets
Knowledge-focused Recruiting nowThis study looks at how deep brain stimulation (DBS) changes movement in people with conditions like Parkinson's disease or essential tremor. About 60 people scheduled for DBS surgery will have extra temporary electrodes placed on the brain to measure muscle activity during stimu…
Sponsor: Jorge Gonzalez-Martinez • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
New study checks drug levels in breast milk for nursing moms
Knowledge-focused Recruiting nowThis study looks at how much of the drug bimekizumab passes into breast milk. Researchers will collect milk samples from 20 breastfeeding mothers with conditions like psoriasis or arthritis over several weeks. The goal is to understand potential exposure for nursing infants, not …
Phase 1 • Sponsor: UCB Biopharma SRL • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Scientists scan brains to unravel why effort hurts in chronic fatigue
Knowledge-focused Recruiting nowThis study uses functional MRI to see how the brain processes unpleasant sensations like pain and physical effort in people with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) compared to healthy volunteers. Researchers will apply mild heat and ask participants to sq…
Early phase 1 • Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
New screening trial aims to speed up matching of cancer patients to the right treatments
Knowledge-focused Recruiting nowThis study tests a new way to screen patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) by analyzing their bone marrow and blood for specific biomarkers. The goal is to quickly match patients with a treatment trial that targets their cancer's unique mark…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Scientists scour lungs for clues to why some get infections
Knowledge-focused Recruiting nowThis study gathers fluid and tissue from the lungs and nose of healthy volunteers and people with a history of lung infections. Researchers will compare samples to find differences in immune function that might explain why some people are more prone to infections. Participants un…
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Scientists launch deep dive into rare genetic condition behind chronic inflammation
Knowledge-focused Recruiting nowThis study aims to better understand trisomy 8 mosaicism, a rare genetic condition where some cells have an extra copy of chromosome 8, and its link to autoinflammatory disease (TRIAD). Researchers will follow affected individuals and their healthy relatives over time, collecting…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Researchers track Insulin-Making cells in type 1 diabetes over years
Knowledge-focused Recruiting nowThis study follows people who previously took part in type 1 diabetes trials to see how long their bodies continue to produce insulin. Researchers will also look at how immune system changes relate to insulin production. The goal is to gather information that could lead to better…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Cancer care at home: what do patients and doctors really think?
Knowledge-focused Recruiting nowThis study interviews cancer care providers, patients, and caregivers to learn their thoughts and feelings about receiving hospital-level care at home. The goal is to understand what people know and believe about home hospital care, so that future programs can be designed to bett…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
New ulcerative colitis drug put through drug interaction test
Knowledge-focused Recruiting nowThis early-phase study is testing whether afimkibart, an experimental drug for ulcerative colitis, changes how the body processes common medications like caffeine, warfarin, and omeprazole. About 25 people with moderate to severe active ulcerative colitis will receive afimkibart …
Phase 1 • Sponsor: Hoffmann-La Roche • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Lupus drug anifrolumab under pregnancy safety spotlight
Knowledge-focused Recruiting nowThis study is tracking 500 pregnant women with lupus to see if the drug anifrolumab is linked to birth defects or pregnancy loss. Researchers will compare women who took anifrolumab during early pregnancy to those who did not. The goal is to gather real-world safety data, not to …
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
New imaging study seeks to unlock muscle fatigue in cancer survivors
Knowledge-focused Recruiting nowThis study uses non-invasive MRI and MRS scans to measure how well muscle cells produce energy in adults who survived childhood acute lymphoblastic leukemia (ALL). Researchers will compare 60 survivors with low muscle mass to healthy volunteers. The goal is to understand why many…
Sponsor: St. Jude Children's Research Hospital • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
New trial uses DNA tests to match cancer patients to targeted drug cocktails
Knowledge-focused Recruiting nowThis large screening trial enrolls up to 2,900 people with advanced solid tumors that have spread or not responded to standard treatment. Researchers use genetic tests on tumor samples to find specific mutations, then assign patients to treatment trials testing drug combinations …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Scientists dig into DNA of moles to uncover hidden mutations
Knowledge-focused Recruiting nowThis study collects moles and blood samples from 50 adults to analyze the genetic mutations that cause moles to form. Researchers will compare DNA from mole tissue with normal DNA from blood to find specific changes. No treatments or interventions are given—the goal is purely to …
Sponsor: University of California, Davis • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Can tissue clues predict which Crohn's patients relapse after surgery?
Knowledge-focused Recruiting nowResearchers are building a tool to predict which Crohn's disease patients will have their disease return after intestinal surgery. The study follows 250 people who undergo intestinal resection as part of routine care, collecting leftover surgical tissue, clinical data, and blood …
Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Major study tracks rare muscle disease to pave way for future treatments
Knowledge-focused Recruiting nowThis observational study aims to better understand primary mitochondrial myopathy, a rare muscle disease. Researchers will follow 1300 patients and healthy controls, measuring muscle strength, balance, and daily function over time. The goal is to develop and validate tools to tra…
Sponsor: Children's Hospital of Philadelphia • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Do all kids with pneumonia need antibiotics? study tracks Real-World decisions
Knowledge-focused Recruiting nowResearchers are observing how often children hospitalized with non-severe pneumonia receive antibiotics and how doctors decide whether a child needs them. The study follows 200 children admitted to two German hospitals, recording treatment choices, medical complications, and pare…
Sponsor: ARCIM Institute Academic Research in Complementary and Integrative Medicine • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Weight-Loss injections may alter contraception effectiveness
Knowledge-focused Recruiting nowThis early-stage study in 50 healthy women with overweight or obesity examines whether two experimental weight-loss injections, AZD6234 and AZD9550, change how the body processes a common birth control pill. Participants will receive the drugs alone and together, and researchers …
Phase 1 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Massive study aims to unlock secrets of parathyroid diseases
Knowledge-focused Recruiting nowThis study follows up to 3,000 people who have, are at risk for, or are related to someone with a parathyroid disorder. Researchers will collect medical records, questionnaires, and samples like blood and saliva to learn what causes these conditions and how they change over time.…
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Scientists launch major study to unravel mysteries of rare lung infections
Knowledge-focused Recruiting nowThis study aims to learn more about non-tuberculous mycobacterial (NTM) infections, which cause repeated lung and other organ infections. Researchers will study up to 1,000 participants to understand the genetics, symptoms, and best treatments for these infections. The study also…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Scientists map HIV's hiding spots in early infection
Knowledge-focused Recruiting nowResearchers want to understand how HIV builds a hidden reservoir in the body when someone starts treatment during the earliest stage of infection. The study follows 70 recently infected people who begin combination antiretroviral therapy right away. Over two years, participants g…
Sponsor: University Hospital, Ghent • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Young hearts at risk: 25-Year study launches to uncover Diabetes-Heart link
Knowledge-focused Recruiting nowThis study aims to learn how type 2 diabetes and obesity in young people affect heart and blood vessel health over time. About 930 participants aged 12 to 25, including those with diabetes, overweight but not diabetic, and healthy lean individuals, will be followed for up to 25 y…
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Scientists hunt for prostate cancer clues in tissue and blood samples
Knowledge-focused Recruiting nowThis study collects blood, urine, saliva, and tumor tissue from 3,000 men with prostate cancer to investigate genetic changes that cause the disease. Participants may also undergo imaging and answer quality-of-life questions. The goal is to better understand prostate cancer and l…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Can PET scan signals predict who beats lung cancer with immunotherapy?
Knowledge-focused Recruiting nowResearchers are investigating whether metabolic markers measured by PET/CT scans and tumor tissue tests can predict how well early-stage non-small cell lung cancer responds to immunotherapy given before surgery. Thirty patients with stage IB to IIIA NSCLC that lacks EGFR and ALK …
Phase 2 • Sponsor: Hospital das Clínicas de Ribeirão Preto • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Scientists track rare eye disease to pave way for future treatments
Knowledge-focused Recruiting nowThis study follows 25 people aged 10 and older with Stargardt-like macular dystrophy (STDG3), a rare inherited eye disease that causes vision loss. Over three years, researchers will measure changes in the retina using eye exams, imaging, and vision tests. The goal is to understa…
Sponsor: National Eye Institute (NEI) • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Can restorative justice help close the lung cancer screening gap?
Knowledge-focused Recruiting nowThis study tests a decision-making support program based on restorative justice principles, designed specifically for Black adults who are at high risk for lung cancer. The goal is to see if this approach increases understanding, trust, and willingness to get screened. Forty-five…
Sponsor: Fred Hutchinson Cancer Center • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
2,000 volunteers to help unlock secrets of metabolic syndrome and prediabetes
Knowledge-focused Recruiting nowThis study will follow 2,000 adults with metabolic syndrome or prediabetes over time to understand how these conditions progress and lead to complications. Researchers will track health records, nutrition, and physical function to find key factors that affect long-term outcomes. …
Sponsor: National Taiwan University Hospital • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Lung cancer surgery registry aims to track Long-Term survival
Knowledge-focused Recruiting nowThis study is a registry that will follow 600 people with early-stage lung cancer who undergo a surgery called segmentectomy. Participants will fill out questionnaires about their health before surgery, shortly after, and six months later. The goal is to measure how long people l…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Can a new radiation machine cut breath holds for cancer patients?
Knowledge-focused Recruiting nowResearchers are studying whether a next-generation radiation delivery system can run a complete treatment workflow while patients hold their breath. The trial enrolls about 20 adults with tumors in the chest or upper abdomen who are already scheduled for stereotactic body radiati…
Sponsor: Varian, a Siemens Healthineers Company • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Blood platelets may hold clues to HIV's hidden hideouts
Knowledge-focused Recruiting nowThis study investigates whether platelets—tiny blood cells involved in clotting—interact with HIV-infected immune cells in ways that affect the virus's ability to persist despite treatment. Researchers will collect blood samples from 90 adults with HIV who have had undetectable v…
Sponsor: Tourcoing Hospital • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Can a scan predict pancreatic cancer? new study aims to find out
Knowledge-focused Recruiting nowThis study is for people with pancreatic cysts or other pancreas issues. Researchers will collect blood, tissue, and scan data from over 1,100 participants to create a large database. The goal is to develop noninvasive tools that predict which cysts may become cancerous, helping …
Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
New study aims to spare breast cancer patients from extensive surgery
Knowledge-focused Recruiting nowThis study is testing whether a less invasive procedure called target axillary dissection (TAD) can accurately check for cancer spread in the lymph nodes of people with locally advanced breast cancer after chemotherapy. The goal is to see if TAD can replace more extensive lymph n…
Sponsor: Hospital Universitari de Bellvitge • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Decades of HIV data could reveal which treatments last
Knowledge-focused Recruiting nowResearchers follow people with HIV who took part in earlier HIV-NAT studies to see how their health changes over many years. The study collects information on treatment history, side effects, other illnesses, and lab results such as viral load and CD4 counts. By tracking a large …
Sponsor: The HIV Netherlands Australia Thailand Research Collaboration • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
New study tracks teen gaze to fight nearsightedness
Knowledge-focused Recruiting nowThis observational study looks at whether different eyeglass prescriptions change how close teenagers hold objects during everyday tasks. It includes 100 adolescents aged 12-17, both with and without myopia. Participants wear motion-capture and eye-tracking gear while performing …
Sponsor: Essilor International • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Why some days hurt more: charting Fibromyalgia's daily swings
Knowledge-focused Recruiting nowFibromyalgia causes widespread pain, fatigue, and trouble with daily activities, and these symptoms can shift from day to day even when their average level stays the same. Researchers at Mardin Artuklu University are studying 150 adults with fibromyalgia to see whether daily chan…
Sponsor: Mardin Artuklu University • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
150,000 children to be tracked from birth to old age in massive health study
Knowledge-focused Recruiting nowResearchers are building a long-term health study of 150,000 children born in Victoria, Australia, and their parents. The study follows participants from birth over their lifetime, collecting data on health, development, and environment through surveys, biosamples, and linked rec…
Sponsor: Murdoch Childrens Research Institute • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
New tool aims to help rural women decide on mammograms
Knowledge-focused Recruiting nowThis study is testing an online tool called MyMammogram that helps women ages 39-49 decide whether to get a mammogram. The tool also shares the woman's risk and preferences with her doctor before the visit. The goal is to see if this approach works well in rural healthcare settin…
Sponsor: Dartmouth-Hitchcock Medical Center • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Louisiana families tracked to uncover Obesity's roots
Knowledge-focused Recruiting nowResearchers at Pennington Biomedical Research Center are following Louisiana families over time to understand how lifestyle and environment affect the risk of developing obesity and other health conditions. The study includes children, teens, young adults, and adults who are expe…
Sponsor: Pennington Biomedical Research Center • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Pregnancy hormone hCG may hold clues to bone and gland health
Knowledge-focused Recruiting nowResearchers are studying whether blood levels of luteinizing hormone (LH) and human chorionic gonadotropin (hCG) are linked to the presence, severity, and long-term outcomes of endocrine disorders such as osteoporosis, thyroid disease, and adrenal gland problems. The study enroll…
Sponsor: Martin Blomberg Jensen • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
AI takes on colorectal surgery: smarter risk assessment or just hype?
Knowledge-focused Recruiting nowThis trial tests whether an AI tool can help surgeons better predict risks for patients undergoing colorectal cancer surgery. About 1,200 patients across Denmark will be randomly assigned to have their risk assessed by a surgeon using standard methods or with AI assistance. The g…
Sponsor: Zealand University Hospital • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Healthy volunteers bitten by mosquitoes in malaria experiment
Knowledge-focused Recruiting nowThis study gives healthy adults a controlled malaria infection using donated blood containing the P. vivax parasite. Researchers will monitor how the infection develops, how the immune system responds, and whether mosquitoes can pick up the parasite from participants. The goal is…
Phase 1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Patients and families build a living database of pulmonary fibrosis
Knowledge-focused Recruiting nowThe Pulmonary Fibrosis Foundation runs an online registry where people with pulmonary fibrosis or interstitial lung disease, their caregivers, and their family members can share information about their health and experiences. Participants enroll themselves and answer questions ov…
Sponsor: Pulmonary Fibrosis Foundation • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Brain scans probe why some Parkinson's patients freeze Mid-Step
Knowledge-focused Recruiting nowResearchers at National Taiwan University Hospital are studying how the brain combines visual information with movement in people who have Parkinson's disease. They will compare 21 people with freezing of gait, 21 without it, and 21 healthy adults of similar age. Participants com…
Sponsor: National Taiwan University Hospital • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Scientists hunt for genes behind rare eye conditions
Knowledge-focused Recruiting nowThis study aims to uncover the genetic causes of a group of eye conditions called MAC (microphthalmia, anophthalmia, and uveal coloboma), which can lead to vision loss or blindness. Researchers will collect DNA samples from 600 people—both those with MAC and their close relatives…
Sponsor: National Eye Institute (NEI) • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Tooth pulp test may reveal which deep cavities heal without a root canal
Knowledge-focused Recruiting nowResearchers at a dental institute in India are studying whether levels of two inflammation markers, IL-1beta and IL-6, in the tooth's pulp can predict how well a full pulpotomy works. The procedure removes the inflamed crown portion of the pulp, caps it with a mineral-based mater…
Sponsor: Postgraduate Institute of Dental Sciences Rohtak • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
New PET scan agent may spot hidden GVHD in joints
Knowledge-focused Recruiting nowThis pilot study is testing a new imaging agent called [18F]4FN in PET/CT scans for people with chronic graft-versus-host disease (GVHD) affecting their joints. The goal is to see if the agent is safe and can help doctors see joint problems more clearly. Sixteen adults with chron…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Can we measure how breast cancer treatment changes the way breasts move?
Knowledge-focused Recruiting nowResearchers at Portsmouth Hospitals NHS Trust and the University of Portsmouth want to know whether they can measure breast biomechanics in women treated for early breast cancer. The study includes 45 women who have had surgery, with or without radiotherapy, for cancer in one bre…
Sponsor: Portsmouth Hospitals NHS Trust • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC